[go: up one dir, main page]

EP1747217A1 - Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments - Google Patents

Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments

Info

Publication number
EP1747217A1
EP1747217A1 EP05747401A EP05747401A EP1747217A1 EP 1747217 A1 EP1747217 A1 EP 1747217A1 EP 05747401 A EP05747401 A EP 05747401A EP 05747401 A EP05747401 A EP 05747401A EP 1747217 A1 EP1747217 A1 EP 1747217A1
Authority
EP
European Patent Office
Prior art keywords
group
alkyl
methyl
atom
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05747401A
Other languages
German (de)
English (en)
Inventor
Roland Pfau
Henning Priepke
Kai Gerlach
Wolfgang Wienen
Annette Schuler-Metz
Herbert Nar
Sandra Handschuh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1747217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to EP05747401A priority Critical patent/EP1747217A1/fr
Publication of EP1747217A1 publication Critical patent/EP1747217A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to new substituted thiophene-2-carboxamides of the general formula
  • the compounds of the above general formula I and their tautomers, their enantiomers, their diastereomers, their mixtures and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, and their stereoisomers have valuable pharmacological properties, in particular an antithrombotic effect and a factor Xa inhibitory effect.
  • the present application relates to new compounds of the general formula I above, their preparation, the pharmaceutical compositions containing the pharmacologically active compounds, their preparation and use.
  • n 1 or 2
  • R 8a each independently represent a hydrogen or halogen atom or a C ⁇ -5 alkyl, hydroxy, hydroxy-C ⁇ -5 alkyl, C ⁇ -5 alkoxy, C ⁇ -C ⁇ -5 alkoxy.
  • 5 -alkyl-, amino-, C ⁇ -5 -alkylamino-, di- (C ⁇ -5 -alkyl) -amino-, amino-C ⁇ -5 -alkyl-, C ⁇ -5 -alkylamino-C ⁇ -5-alkyl-, Di- (C ⁇ -5 -alkyl) -amino-C 1-5 -alkyl-, aminocarbonyl-, C ⁇ -5 -AlkyIaminocarbonyl-, di- (C ⁇ -5 -alkyl) -aminocarbonyl- or C ⁇ - 5 -alkylcarbonylamino group means in the case of the above-mentioned substituted 5- to 7-membered radicals A
  • R 8c each independently represents a hydrogen atom, a ds-alkyl, -CC-5-alkylcarbonyl, -CC-5-alkyloxycarbonyl or d- 5 -alkylsulfonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen or sulfur atom or an -NR 8c group
  • R 1 is a halogen atom, a C 3 alkyl or C 3 alkoxy group, where the hydrogen atoms of the C 3 alkyl or C 3 alkoxy group can optionally be wholly or partly replaced by fluorine atoms, a C 2 -3- alkenyl, C 2- 3 -alkynyl, nitrile, nitro or amino group,
  • R 2 represents a hydrogen or halogen atom or a C 3 -3 alkyl group
  • R 3 represents a hydrogen atom or a C ⁇ -3 alkyl group
  • R 4 and R 5 are each independently a hydrogen atom, a C 2- 6 alkenyl or C 2-6 alkynyl group, a linear or branched C ⁇ -6 alkyl group, wherein the hydrogen atoms of the straight-chain or branched Ci-e-alkyl group may optionally be wholly or partly replaced by fluorine atoms, and which may optionally be replaced by a C 3-5 cycloalkyl group, a nitrile, hydroxyl, a C ⁇ - 5 alkyloxy group, the hydrogen atoms of the C ⁇ - 5 alkyloxy group can optionally be wholly or partly replaced by fluorine atoms, an allyloxy, propargyloxy, benzyloxy, C ⁇ -5 -alkylcarbonyloxy-, C ⁇ -5 -alkyloxycarbonyloxy-, carboxy-C ⁇ -5-alkyloxy-, C ⁇ - 5 -alkyloxycarbonyl-C ⁇ - 5- Alkyloxy-
  • a phenyl, heteroaryl, phenyl-C 5 alkyl or heteroaryl C 5 -alkyl group which, in the phenyl or heteroaryl part, is optionally selected one to three times by identical or different substituents selected from the group consisting of halogen atoms, 5 alkyl, di (C ⁇ - 5 alkyl) amino, C ⁇ -5 -alkyloxy, mono-, di- or trifluoromethoxy, carboxy- and C ⁇ - 5 -Alkyloxycarbonyl rule may be substituted hydroxy,
  • a 3- to 7-membered cycloalkyl, cycloalkyleneimino, cycloalkyl- C ⁇ - 5 alkyl or cycloalkyleneimino -C ⁇ -3 alkyl group in the 4- to 7-membered cycles in the cyclic part of a methylene group optionally replaced by an -N (R 8c ) group, an oxygen or sulfur atom or an -S (0) ⁇ or -S (0) 2 group , or in the case of 4- to 7-membered cycles in the cyclic part, two adjacent methylene groups together optionally replaced by a -C (0) N (R 8b ) - or -S (0) 2 N (R 8b ) group may be, or in which in the case of 6- to 7-membered cycles in the cyclic part three adjacent methylene groups together, optionally with a substituted -OC (0) N (R 8b ) - or -N (R 8b ) C (0) N (
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3-8 cycloalkyl or C 3-8 cycloalkenyl group, one of the methylene groups of a C 4-8 cycloalkyl group can be replaced by an oxygen or sulfur atom or an -N (R 8c ) -, or a carbonyl, sulfinyl or sulfonyl group, and / or
  • C -8 cycloalkyl group together can be replaced by a -C (0) N (R 8b ) - or - S (0) 2 N (R 8b ) group, and / or
  • R 6 represents a hydrogen, fluorine, chlorine, bromine or iodine atom, a nitrile group, a C ⁇ -3 -AlkyIuite or d -3 alkoxy group, while the hydrogen atoms of the alkyl or C ⁇ C ⁇ -3 -3 Alkoxy group can optionally be completely or partially replaced by fluorine atoms,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a C -3 alkyl, phenyl or phenyl C 3 alkyl group, an oxygen or sulfur atom or an optionally by a C -3 alkyl, phenyl, amino C 2-3 -alkyl-, C ⁇ -3 -alkylamino-C 2 -3-alkyl-, di- (C ⁇ -3 -alkyl) -amino-C 2 - 3 -alkyl-, a C 3 - 6 - cycloalkylenimino-C 1-3 alkyl or phenyl-C 3 alkyl group substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom or an im
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, may be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, contained in the definitions mentioned above , can be the same or different,
  • Examples of monocyclic heteroaryl groups are the pyridyl, ⁇ / -oxy-pyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, [1, 2,3] triazinyl, [1, 3,5] triazinyl, [ 1, 2,4] triazinyl, pyrrolyl, imidazolyl, [1, 2,4] triazolyl,
  • bicyclic heteroaryl groups are the benzimidazolyl, benzofuranyl, benzo [c] furanyl, benzothiophenyl, benzo [c] thiophenyl, benzothiazolyl, benzo [c] isothiazolyl, benzo [ ⁇ f] isothiazolyl, benzooxazolyl, c] isoxazolyl, benzo [ ⁇ f] isoxazolyl, benzo [1, 2.5] oxadiazolyl, benzo [1, 2.5] thiadiazolyl, benzo [1, 2.3] thiadiazolyl, benzo [ ⁇ [1 , 2,3] triazinyl, benzo [1, 2,4] triazinyl, benzotriazolyl, cinnolinyl, quinolinyl, ol / -oxy-quinolinyl, isoquinolinyl, quinazolinyl, ⁇ / -oxy-quinazolinyl
  • Examples of the C 6 alkyl groups mentioned above in the definitions are the methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl , 2-pentyl, 3-pentyl, neo-pentyl, 3-methyl-2-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 3-methyl-2-pentyl, 4- Methyl 2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,2-dimethyl-3-butyl or 2,3-dimethyl-2-butyl group.
  • Examples of the d- 5 -alkyloxy groups mentioned above in the definitions are the methyloxy, ethyloxy, 1-propyloxy, 2-propyloxy, ⁇ -butyloxy, sec-butyloxy, terf-butyloxy, 1-pentyloxy , 2-pentyloxy, 3-pentyloxy or ⁇ eo-pentyloxy group.
  • C 2 - 6 alkenyl groups are ethenyl, 1-propen-1-yl, 2-propen-1-yl, 1-butene-1-yl, 2-butene 1-yl, 3-buten-1-yl, 1-pentene-1-yl, 2-pentene-1-yl, 3-pentene-1-yl, 4-pentene-1-yl, 1-hexen-1-yl, 2-hexen-1-yl, 3-hexen-1-yl, 4-hexen-1-yl, 5-hexen-1-yl, but-1-ene -2-yl-, but-2-en-2-yl-, but-1-en-3-yl-, 2-methyl-prop-2-en-1-yl-, pent-1-en-2 -yl-, Pent-2-en-2-yl-, Pent-3-en-2-yl-, Pent-4-en-2-yl-, Pent-1-en-3-yl-,
  • C 2 - 6 alkynyl groups are ethynyl, 1-propynyl, 2-propynyl, 1-butyn-1-yl, 1-butyn-3-yl, 2-butyn -1 -yl-, 3-butyn-1 -yl-, 1 -pentin-1 -yl-, 1 -pentin-3-yl-, 1 -pentin-4-yl-, 2-pentin-1-yl- , 2-pentyn-3-yl-, 3-pentyn-1-yl-, 4-pentyn-1-yl-, 2-methyl-1-butyn-4-yl-, 3-methyl-1-butyn-1 -yl-, 3-Methyl-1-butin-3-yl-, 1-Hexin-1-yl-, 2-Hexin-1-yl-, 3-Hexin-1-yl-, 4-Hexin-1- yl-, 5-he
  • a converted in vivo into a carboxy group is, for example, an esterified carboxy group with an alcohol in which the alcoholic moiety is preferably a C ⁇ -6 alkanol, a phenyl-C ⁇ -3 -alkanol, a C 3-9 cycloalkanol, a C5 -7-CycloalkenoI, a C 3 - 5 alkenol, a phenyl C 3 - 5 alkenol, a C 3 .
  • R 9 is a C ⁇ -8 alkyl, C 5-7 cycloalkyl, phenyl or phenyl-C ⁇ alkyl group -3,
  • R 10 is a hydrogen atom, a d- 3 alkyl, C 5-7 cycloalkyl or phenyl group and
  • R 11 represents a hydrogen atom or ad -3 alkyl group, to understand.
  • the preferred radicals which can be split off from a carboxy group in vivo are a C 6 alkoxy group such as the methoxy, ethoxy, n-propyloxy, isopropyloxy, / i-butyloxy, ⁇ -pentyloxy, ⁇ -hexyloxy or cyclohexyloxy group or a Phenyl-C ⁇ - 3 -IIkoxy distr like the benzyloxy group into consideration.
  • a converted in vivo to a hydroxyl group for example an esterified hydroxyl group with a carboxylic acid in which the carboxylic acid moiety preferably a C ⁇ - alkanoic acid, phenyl d- 3 alkanoic acid, a C 3 9 cycloalkyl carboxylic acid, a C 5 - 7 -Cycloalkencarbonklare, a C 3-7 alkenoic, a phenyl C 3-5 alkenoic, a C 3 -7 ⁇ alkynoic acid or phenyl-C 3-5 -alkinklare, where individual methylene groups of the carboxylic acid group may be replaced by oxygen atoms with provided that there is no commitment to the carboxylic acid in which the carboxylic acid moiety preferably a C ⁇ - alkanoic acid, phenyl d- 3 alkanoic acid, a C 3 9 cycloalkyl carboxylic acid, a C 5 - 7 -Cycloalken
  • residues that can be split off from a hydroxyl group in vivo are a C 7 -acyl group such as the formyl, acetyl, ⁇ -propionyl, isopropionyl, n-propanoyl, n-butanoyl, ⁇ -pentanoyl, n-hexanoyl - or cyclohexylcarbonyl group or a benzoyl group and also a methoxyacetyl, 1-methoxypropionyl, 2-methoxypropionyl or 2-methoxyethoxyacetyl group.
  • a C 7 -acyl group such as the formyl, acetyl, ⁇ -propionyl, isopropionyl, n-propanoyl, n-butanoyl, ⁇ -pentanoyl, n-hexanoyl - or cyclohexylcarbonyl group or a benzoy
  • Those compounds of the general formula I in which A, R 4 and / or R 5 contain a group which can be converted into a carboxy or hydroxyl group in vivo are prodrugs for those compounds of the general formula I in which A, R 4 and / or R 5 contains a carboxy or hydroxyl group.
  • n 1 or 2
  • R 8a each independently of one another represents a hydrogen or halogen atom or ad -5 -alkyl, hydroxy, hydroxy-C- ⁇ -5 -alkyl-, d -5 -alkoxy-, C ⁇ -5 -alkoxy-d- 5 - alkyl, amino, C -5 alkylamino, di (d -5 alkyl) amino, amino d 5 alkyl, C 1-5 alkylamino C -5 alkyl, di - (C ⁇ -5 alkyl) amino-C ⁇ -5 alkyl, aminocarbonyl, C ⁇ , di- (d -5 alkyl) aminocarbonyl or alkylcarbonylamino means Ci.s--5 -alkylaminocarbonyl-, wherein in the above-mentioned substituted 5- to 7-membered radicals A, the heteroatoms F, Cl, Br, I, O or N, optionally introduced with R 8a as substituents, are not separated from a heteroatom from
  • R 8c each independently represents a hydrogen atom, a C 5 alkyl, Ci.s alkylcarbonyl, d -5 alkyloxycarbonyl or C -5 alkyl sulfonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen or sulfur atom or an -NR 8c group
  • R 1 is a halogen atom, a C 1-3 alkyl or d 3 alkoxy group, where the hydrogen atoms of the C 3 alkyl or C 3 alkoxy group can optionally be wholly or partly replaced by fluorine atoms, a C 2 - 3 -Alkenyl, C 2 - 3 -alkynyl, nitrile, nitro or amino group,
  • R 2 represents a hydrogen or halogen atom or a C 3 alkyl group
  • R 3 represents a hydrogen atom or ad -3 alkyl group
  • R 4 and R 5 each independently of one another are a hydrogen atom, a C2-6-alkenyl or C2-6-alkynyl group, a straight-chain or branched C 6 alkyl group
  • the hydrogen atoms of the straight-chain or branched Ci-e-alkyl group may optionally be wholly or partly replaced by fluorine atoms, and which may optionally be replaced by a C 3 -5-cycloalkyl group, a nitrile, hydroxyl, a C 1-5 -alkyloxy group
  • the hydrogen atoms of the C ⁇ -5 - Alkyloxy group can optionally be wholly or partly replaced by fluorine atoms, an allyloxy, propargyloxy, benzyloxy, C ⁇ -5 -alkylcarbonyloxy, C ⁇ -5-alkyloxycarbonyloxy, carboxy-C ⁇ -5 -alkyloxy-, d -5 -alkyloxycarbonyl- C ⁇
  • a phenyl, heteroaryl, phenyl-d- 5 -alkyl or heteroaryl-d- 5 -alkyl group which, in the phenyl or heteroaryl part, is optionally selected one to three times by identical or different substituents selected from the group consisting of halogen atoms, d- 5 -alkyl-, di- (C ⁇ -5 -alkyl) amino, hydroxy, C ⁇ - 5 alkyloxy, mono-, di- or trifluoromethoxy, carboxy and C ⁇ - 5 alkyloxycarbonyl groups can be substituted,
  • a 3- to 7-membered cycloalkyl, cycloalkyleneimino, cycloalkyl- d- 5 -alkyl or cycloalkylenimino-C ⁇ -3 alkyl group in the 4- to 7-membered cycles in the cyclic part of a methylene group optionally replaced by an -N (R 8c ) group, an oxygen or sulfur atom or an -S (O) - or -S (0) 2 - group , or in the case of 4- to 7-membered cycles in the cyclic part, two adjacent methylene groups together optionally replaced by a -C (0) N (R 8b ) - or -S (0) 2 N (R 8b ) group may be, or in which in the case of 6- to 7-membered cycles in the cyclic part three adjacent methylene groups together, optionally with a substituted -OC (0) N (R 8b ) - or -N (R 8b ) C
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3 - 8 cycloalkyl or C 3 - 8 cycloalkenyl group, one of the methylene groups of a C 4 - 8 cycloalkyl group can be replaced by an oxygen or sulfur atom or an -N (R 80 ) -, or a carbonyl, sulfinyl or sulfonyl group, and / or
  • Carboxy-, ds-alkyloxycarbonyl-, aminocarbonyl-, C ⁇ - 5 -alkylaminocarbonyl-, di- (d -5 -alkyl) -aminocarbonyl-, C 3-6 -cycloalkyleniminocarbonyl-, aminosulfonyl-, d- 5 -Alkylaminosulfonyl-, di- (C ⁇ -5 -alkyl) -aminosulfonyl-, C 3-6 -cycloalkyleniminosulfonyl groups can be substituted,
  • V- (C ⁇ -5 alkylsulfonyl) -C ⁇ .5 alkylamino or C 3- 6-Cycloalkylcarbonylamino phenomenon may be substituted
  • a substituent attached to the cyclic group which is characterized in that one heteroatom from the group oxygen, nitrogen, sulfur and halogen atom is bonded directly to the cyclic group, from another hetero atom from the group oxygen, nitrogen and sulfur, with the exception of the sulfone group, separated by exactly one, optionally substituted, methylene group, and / or in which two oxygen atoms are directly connected to one another is excluded,
  • R 6 is a fluorine, chlorine, bromine or iodine atom, a nitrile group, a C -3 alkyl group, or a C 3 -3 alkoxy group, the hydrogen atoms of the C 3 alkyl or C 3 alkoxy group entirely or can be partially replaced by fluorine atoms,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a C 3 alkyl, phenyl or phenyl C 3 alkyl group, an oxygen or sulfur atom or an optionally substituted by a C 3 alkyl, phenyl, amino C 2 - 3 -alkyl-, C ⁇ -3 -alkylamino-C 2 - 3 -alkyl-, di- (C ⁇ - 3 -AIkyl) -amino-C 2 - 3 -AIkyl-, a C 3-6 - Cycloalkylenimino-C ⁇ - 3 - contains alkyl or phenyl-C -3 alkyl group substituted imino group or an oxygen or sulfur atom and in addition
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and which have more than two carbon atoms, unless stated otherwise, can be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, can be the same or different,
  • A is a radical of the general formula
  • n 1 or 2
  • R 8a each independently represent a hydrogen or halogen atom or a C ⁇ -5 alkyl, hydroxy, hydroxy-d -5 alkyl, C ⁇ -5 alkoxy, C 1-5 alkoxy-C- ⁇ - 5 -alkyl-, amino-, C ⁇ -5 -alkylamino-, di- (C ⁇ -5 -alkyl) -amino-, amino-C ⁇ -5 -alkyl-, C ⁇ -5 -alkylamino-C ⁇ .
  • R 8b each independently represents a hydrogen atom or a Ci-s-alkyl group means
  • R 8c each independently represents a hydrogen atom, ad -5 alkyl, d: 5 alkylcarbonyl, d -5 alkyloxycarbonyl or d -5 alkyl sulfonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen atom or an -NR 8c group
  • R 1 a fluorine, chlorine, bromine or iodine atom, a d -3 alkyl or d-3 alkoxy, wherein the hydrogen atoms of the alkyl or d- d -3 3 alkoxy group optionally fully or partially substituted by fluorine atoms can be replaced, or means a nitrile group,
  • R 2 represents a hydrogen or halogen atom or a methyl group
  • R 3 represents a hydrogen atom or a methyl group
  • R 4 is a C- 6- alkenyl or C 2 -6-alkynyl group, a straight-chain or branched d- ⁇ -alkyl group, where the hydrogen atoms of the straight-chain or branched d- 6 -alkyl group can optionally be wholly or partly replaced by fluorine atoms, and optionally by a C3-5 cycloalkyl group, a nitrile, hydroxyl, a C ⁇ -5 -alkyloxy group, the hydrogen atoms of the C ⁇ -5 -alkyloxy group optionally entirely or can be partially replaced by fluorine atoms, a benzyloxy, Ci-s-alkylcarbonyloxy, d -5 -alkyloxycarbonyloxy, carboxy-Ci-s-alkyloxy, C 1-5 alkyloxycarbonyl -CC.
  • a phenyl, heteroaryl, phenyl-C ⁇ -5 -alkyl or heteroaryl-d- 5 -alkyl group which in the phenyl or heteroaryl part optionally one to three times selected by the same or different substituents from the group consisting of halogen atoms, C ⁇ - 5-alkyl, di- (C ⁇ -5-alkyl) amino, hydroxy, C ⁇ -5 -alkyloxy, mono-, di- or trifluoromethoxy, carboxy- and may be substituted d- 5 -Alkyloxycarbonyl phenomenon,
  • a 3- to 7-membered cycloalkyl, cycloalkyleneimino, cycloalkyl- C ⁇ - 5 alkyl or cycloalkylenimino-C 1-3 alkyl group in which in 4- to 7-membered cycles in the cyclic part a methylene group optionally by a - N (R 8c ) group, an oxygen or sulfur atom or an -S (O) - or -S (0) 2 group can be replaced, or in the case of 4- to 7-membered cycles in the cyclic part two adjacent ones Methylene groups together can optionally be replaced by a -C (0) N (R 8b ) - or -S (0) 2 N (R 8b ) group, or in which in the case of 6- to 7-membered cycles in the cyclic part three adjacent methylene groups together optionally substituted by one - OC (0) N (R 8b ) - or -N (R 8b ) C (0) N (R 8
  • R 5 is a hydrogen atom, a C 2 - ⁇ -alkenyl or C 2 - 6 alkynyl group, a linear or branched C ⁇ -6 -A kyl distr wherein the hydrogen atoms of the straight-chain or branched C ⁇ - C6 alkyl group optionally fully or partially,! Fluorine atoms can be replaced, and which can optionally be substituted by a d- 5 -alkyloxy group, where the hydrogen atoms of the d- 5 -alkyloxy group can be replaced in whole or in part by fluorine atoms, or
  • R 4 and R 5 together with the carbon atom to which they are attached, a C 3 - 8 cycloalkenyl group form - 8 cycloalkyl or C 3 wherein one of the methylene groups of a C 4-8 cycloalkyl group can be replaced by an oxygen or sulfur atom or an -N (R 8c ) -, or a carbonyl or sulfonyl group, and / or
  • C 4-8 cycloalkyl group together can be replaced by a -C (0) N (R 8b ) - or - S (0) 2 N (R 8b ) group, and / or
  • R 6 represents a fluorine, chlorine, bromine or iodine atom, a nitrile group, a C 3 alkyl group, or a d -3 alkoxy group, the hydrogen atoms of the C 1 alkyl or C 3 alkoxy group optionally being entirely or can be partially replaced by fluorine atoms,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a d- 3 alkyl, phenyl or phenyl-C 3 -3 alkyl group, an oxygen or sulfur atom or an optionally substituted by a C 3 -3 alkyl, phenyl, amino C 2-3 -alkyl-, C ⁇ -3 -alkylamino-C 2-3 ⁇ alkyl-, di- (C ⁇ -3 -alkyl) -amino-C 2-3 -alkyl-, a C 3-6 - cycloalkylenimino-C ⁇ -3 - contains alkyl or phenyl-C -3 alkyl group substituted imino group or an oxygen or sulfur atom and in addition
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, may be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, contained in the definitions mentioned above , can be the same or different,
  • R 8b each independently represents a hydrogen atom or a d- 3 -alkyl group
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen atom or an -NR 8c group
  • R 1 is a fluorine, chlorine, bromine or iodine atom, a C -3 alkyl or a d 3 alkoxy group, the hydrogen atoms of the C 1-3 alkyl or d -3 alkoxy group optionally completely or can be partially replaced by fluorine atoms,
  • R 2 represents a hydrogen or halogen atom or a methyl group
  • R 3 represents a hydrogen atom
  • R 4 is a C 2-4 alkenyl or C 2 - 4 alkynyl group, a straight-chain or branched d -4 -alkyl group, it being possible for the hydrogen atoms of the straight-chain or branched C 1 -C -alkyl group to be replaced in whole or in part by fluorine atoms, and which may be replaced by a C 3-5 - cycloalkyl group, a nitrile, hydroxy, a C ⁇ -3 -alkyloxy group, where the hydrogen atoms of the C ⁇ -3 -alkyloxy group may optionally be wholly or partly replaced by fluorine atoms, a benzyloxy, d- 3 -Alkylcarbonyloxy-, C ⁇ -3 -alkyloxycarbonyl-C- ⁇ -3 -alkyloxy-, C ⁇ -3 -alkyloxycarbonyl-, aminocarbonyl-, C ⁇ -3 -alkylamino
  • R 5 is a hydrogen atom, a C 2 - 4 aikenyl or C 2-4 alkynyl group, a straight-chain or branched C 1 -C alkyl group, the hydrogen atoms of the straight-chain or branched C 4 -4 alkyl group optionally being completely or partially replaced by fluorine atoms may, and which may optionally be substituted by a C -3 alkyloxy group, where the hydrogen atoms of the C 1-3 alkyloxy group may be replaced in whole or in part by fluorine atoms, or
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3 -s-cycloalkyl or C 3 -8-cycloalkenyl group, one of the methylene groups of a C -8 -cycloalkyl group being represented by an oxygen or sulfur atom or a sulfonyl or -N (R 8c ) group can be replaced, and / or two directly adjacent methylene groups C 4 . 8 -cycloalkyl group together can be replaced by a -C (0) N (R 8b ) - or - S (0) 2 N (R 8b ) group, and / or
  • R 6 represents a fluorine, chlorine, bromine or iodine atom, a methyl group or a methoxy group, it being possible for the hydrogen atoms of the methyl or methoxy group to be replaced in whole or in part by fluorine atoms,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a C 1-3 alkyl, phenyl or phenyl C 1-3 alkyl group, an oxygen or sulfur atom or an optionally d by a '-3 alkyl, phenyl, amino-C 2 - 3 alkyl, C ⁇ -3 alkylamino-C 2 - 3 -alkyl, di- (C ⁇ -3 alkyl) amino -C 2 - 3 -alkyl-, a C 3-6 - cycloalkylenimiho-C ⁇ -3 -alkyl or phenyl-C ⁇ -3 -alkyl group substituted imino group or an oxygen or sulfur atom and additionally a nitrogen
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, may be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, contained in the definitions mentioned above , can be the same or different,
  • A is a radical of the general formula
  • n 1 or 2
  • R 8a each independently of one another is a hydrogen or fluorine atom or a -C 3 alkyl, hydroxy, hydroxy C 3 -3 alkyl, d -3 alkoxy, C 3 alkoxy d 3 alkyl 3 , Amino, C 3 -3 alkylamino, di (C 3 -3 alkyl) amino, amino C 3 -3 alkyl, C 3 alkylamino C 3 alkyl, or di ( C ⁇ -3-alkyl) amino-C ⁇ -3 alkyl group means, in the case of the above-mentioned substituted 5- to 7-membered radicals A, the heteroatoms optionally introduced with R 8a as substituents F, O or N are not separated by exactly one carbon atom from a hetero atom from the group N, O, S,
  • R 8c in each case independently of one another means a hydrogen atom, ad -3 -Alkyl-, -C-- 3- alkylcarbonyl-, or a -C-- 4- alkyloxycarbonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • R 8b each independently represents a hydrogen atom or a d- 3 -alkyl group
  • X 4 represents an oxygen atom or an -NR 8c group
  • R 1 represents a fluorine, chlorine, bromine or iodine atom, a methyl or a methoxy group, where the hydrogen atoms of the methyl or methoxy group can optionally be completely or partially replaced by fluorine atoms,
  • R 2 represents a hydrogen or fluorine atom or a methyl group
  • R 3 means a hydrogen atom
  • R 4 is a C 2- 4 alkenyl or C 2-4 alkynyl group, a straight-chain or branched C -4 alkyl group, the hydrogen atoms of the straight-chain or branched d -4 alkyl group optionally being replaced in whole or in part by fluorine atoms can, and optionally - by a nitrile, hydroxyl, ad- 3 -alkyloxy group, where the hydrogen atoms of the C ⁇ -3 -alkyloxy group can optionally be wholly or partly replaced by fluorine atoms, a benzyloxy-, -C ⁇ -3- alkylcarbonyloxy- , C ⁇ -3 -Alkyloxycarbonyl-, Aminocarbonyl-, -C ⁇ -3 -Alkylaminocarbonyl-, Di- (C ⁇ -3 -alkyl) -aminocarbonyl-, C 3 - 6 -cycloalkyleniminocarbony
  • R is a hydrogen atom, a straight-chain or branched C ⁇ -4 alkyl group, where the hydrogen atoms of the straight-chain or branched C ⁇ - alkyl group may optionally be replaced in whole or in part by fluorine atoms, and optionally by a d- 3 -alkyloxy group, the hydrogen atoms being the C 3 alkyloxy group may optionally be wholly or partly replaced by fluorine atoms, may be substituted, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached, a C 3 - 8 cycloalkyl group form wherein one of the methylene groups of a C 4-8 cycloalkyl group can be replaced by an oxygen or sulfur atom or a sulfonyl or -N (R 8o ) group, and / or
  • Cycloalkyl group together by an -OC (0) N (R 8b ) -, - N (R 8b ) C (0) N (R 8b ) - or -N (R 8b ) S (0) 2 N (R 8 ) - Group can be replaced
  • R represents a fluorine, chlorine, bromine or iodine atom, a methyl group or a> methoxy group, where the hydrogen atoms of the methyl or methoxy group can optionally be replaced in whole or in part by fluorine atoms,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a C 3 alkyl, phenyl or phenyl C 3 alkyl group, an oxygen or sulfur atom or an optionally substituted by a d 3 alkyl, phenyl, amino C 2 -3 -alkyl-, d- 3 -alkylamino-C 2-3 -alkyl-, di- (C ⁇ - 3 -alkyl) -amino-C 2 - 3 -alkyl-, a C 3-6 - cycloalkylenimino-d-3- alkyl or phenyl -C -3 alkyl group substituted Imino group or an oxygen or sulfur atom and in addition a nitrogen atom
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, can be straight-chain or branched, and the alkyl groups in the above-mentioned dialkylated radicals, for example the dialkylamino groups, are identical or are contained in the abovementioned definitions can be different
  • a 6th embodiment of the present invention comprises those compounds of the general formula I in which
  • A is a radical of the general formula
  • n 1 or 2
  • X 1 is a carbonyl, thiocarbonyl
  • C NR 8c -
  • C N-OR 80 -
  • C N-N0 2 -
  • C N-CN- o oddeerr S SuullffoonnvyIl ⁇ grruuopDpee
  • R 8c each independently represents a hydrogen atom, a C -3 alkyl, C 3 -3 alkylcarbonyl or ad -4 alkyloxycarbonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • R 8b represents a hydrogen atom or a C -3 alkyl group
  • X 4 represents an oxygen atom or an -NR 8c group
  • R 1 represents a fluorine, chlorine, bromine or iodine atom, a methyl or a methoxy group, where the hydrogen atoms of the methyl or methoxy group can optionally be wholly or partly replaced by fluorine atoms, represents a hydrogen or fluorine atom,
  • R represents a hydrogen atom
  • R 4 is a straight-chain or branched C 1 -C alkyl group, where the hydrogen atoms may optionally be replaced in whole or in part by fluorine atoms, and which may optionally be replaced by a hydroxyl group, a C 3 -3 alkyloxy group, the hydrogen atoms of the C 3 -C 3 alkyloxy group being entirely or can be partially replaced by fluorine atoms, a benzyloxy, C ⁇ -3 -Alkylcarbonyloxy-, C ⁇ - 3 -AlkyIoxycarbonyl-, aminocarbonyl, C ⁇ -3-alkylaminocarbonyl-, di- (C ⁇ -3-alkyl) -aminocarbonyl-, C 3rd -6- CycloalkyIeniminocarbonyl-, aminosulfonyl-, C 1 - 3 -AI- kylaminosulfonyl-, di- (C ⁇ -3 -alkyl) -aminos
  • R 5 is a hydrogen atom, a straight-chain or branched C ⁇ -4 alkyl group, where the hydrogen atoms can optionally be replaced in whole or in part by fluorine atoms, and which may optionally be replaced by a C ⁇ -3 alkyloxy group, the hydrogen atoms in the C ⁇ -3 alkyloxy group optionally being entirely or may be partially replaced by fluorine atoms, may be substituted, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3 -7-cycloalkyl group, one of the methylene groups of a C 4 -6-cycloalkyl group being represented by an oxygen or sulfur atom or a sulfonyl or -N ( R 8c ) group can be replaced, where 1 to 2 carbon atoms of a C 3 - 7 cycioalkyl group optionally independently of one another by a d- 3 alkyl, hydroxy, C 3 -3 alkyloxy, di (d -3 - alkyl) amino group can be substituted, with the proviso that such a C 3-7 cycloalkyl group formed together from R 4 and R 5 , in which two hetero atoms in the cycle from the group oxygen and nitrogen are separated from one another by exactly one optionally substituted -CH 2 group, and / or in which one or both methylene groups of the cycle, which are directly connected to the carbon atom to which the radicals R
  • R 6 represents a chlorine or bromine atom
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine, where the alkyl and alkoxy groups contained in the definitions mentioned above, which have more than two carbon atoms, unless stated otherwise, can be straight-chain or branched and the alkyl groups in the aforementioned dialkylated radicals, for example the dialkylamino groups, are the same or different could be,
  • A is a radical of the general formula
  • R 8a each independently of one another is a hydrogen or fluorine atom or a d-3-alkyl, hydroxy, hydroxy-C ⁇ -3 -alkyl-, C ⁇ -3 -alkoxy-, C ⁇ -3 -alkoxy-C ⁇ - 3-alkyl- , Amino-, C ⁇ -3- alkylamino-, di- (C ⁇ -3 -alkyl) -amino-, amino-C ⁇ -3 -alkyl-, C ⁇ -3 -alkylamino-C ⁇ -3 -alkyl-, Di- (C ⁇ -3 -alkyl) -amino-C ⁇ -3 -alkyl group means, in the case of the above-mentioned substituted 5- to 7-membered radicals A, the heteroatoms F, O or N, optionally introduced with R 8a , are not replaced by exactly one carbon atom of one Heteroatoms are separated from the group N,
  • R 8c is a hydrogen atom, a C- 3 alkyl, -C. Is 3- alkylcarbonyl or a C 1-4 -alkyloxycarbonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • R 8b represents a hydrogen atom or ad 3 -alkyl group
  • X 4 represents an oxygen atom or an -NR 8c group
  • R 1 represents a chlorine or bromine atom, a methyl, trifluoromethyl or a methoxy group
  • R 2 represents a hydrogen or fluorine atom
  • R 3 represents a hydrogen atom
  • R 4 is a methyl group which may optionally be substituted by a hydroxy, methoxy, benzyloxy, methoxycarbonyl or pyridin-4-yl group, or an i-methyl-pyrazin-3-yl, phenyl, pyridin-3-yl group yl or pyrazin-2-yl group means
  • R 5 represents a hydrogen atom or a methyl group
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3-6 cycloalkyl group, one of the methylene groups of a C -6 cycloalkyl group being replaced by an oxygen atom or an -N (R 8c ) group can, with the proviso that such a C 3 - 6 cycloalkyl group, formed together from R 4 and R 5 , in which one or both methylene groups of the cycle which are directly connected to the carbon atom on which the radicals R 4 and R 5 are attached, are replaced by a hetero atom from the group consisting of oxygen, nitrogen and sulfur, is excluded,
  • R 6 represents a chlorine or bromine atom
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine, where the alkyl and alkoxy groups contained in the definitions mentioned above, which have more than two carbon atoms, unless stated otherwise, can be straight-chain or branched and the alkyl groups in the dialkylated radicals mentioned above, for example the dialkylamino groups, can be identical or different .
  • An eighth embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 1, 2, 3, 4, 5, 6 and 7 in which the radical A is the group
  • A is a radical of the general formula
  • n 1 or 2
  • R 8a each independently of one another is a hydrogen or halogen atom or ad -5 alkyl, hydroxy, hydroxy -CC -5 alkyl, -C -5 -alkoxy-, -C -5 -alkoxy-C ⁇ - 5 -alkyl- , Amino-, C ⁇ -5 -alkylamino-, di- (d -5 -alkyl) -amino-, amino-d -5 -alkyl-, C ⁇ -5 -alkylamino-C ⁇ -5-alkyl-, di- (C ⁇ -5-alkyl) -amino-C ⁇ -5-alkyl-, aminocarbonyl-, d -5 -alkylaminocarbonyl-, di- (C ⁇ -5 -alkyl) -aminocarbonyl- or d-5-alkylcarbonylamino group, with the above substituted 5- to 7-membered radicals A, the heteroatoms F
  • R 8b each independently represents a hydrogen atom or a C 5 alkyl group
  • R 80 each independently represent a hydrogen atom, a C ⁇ -5 alkyl. d-5-alkylcarbonyl, C ⁇ -5 alkyloxycarbonyl or d -5 alkylsulfonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen or sulfur atom or an -NR 8c group
  • R 1 is a fluorine, chlorine, bromine or iodine atom, ad -3 alkyl or C 3 alkoxy group, the hydrogen atoms of the C 3 alkyl or d 3 alkoxy group optionally in whole or in part by fluorine atoms can be replaced, means a C 2 - 3 alkenyl, C 2 - 3 alkynyl, nitrile, nitro or amino group,
  • R 2 represents a hydrogen or halogen atom or a C 3 alkyl group
  • R 3 represents a hydrogen atom or ad -3 alkyl group
  • R 4 and R 5 are each independently a hydrogen atom, a C 2-6 -alkenyl or C 2 - 6 alkynyl group, a linear or branched d -6 alkyl group, wherein the hydrogen atoms of the straight-chain or branched C 6 alkyl group optionally Can be replaced in whole or in part by fluorine atoms, and which may be replaced by a C 3- 5 cycloalkyl group, a nitrile, hydroxy, a Ci.
  • ⁇ -alkyloxy group where the hydrogen atoms of the d- ⁇ -alkyloxy group can optionally be wholly or partly replaced by fluorine atoms, an allyloxy, propargyloxy, benzyloxy, Ci ⁇ alkylcarbonyloxy, C ⁇ - 5 alkyloxycarbonyloxy, carboxy-C ⁇ -5 -alkyloxy-, d- 5 -alkyloxycarbonyl-d. ⁇ -alkyloxy-, mercapto-, C ⁇ -5 -alkylsulfanyl-, C ⁇ -5 -alkylsulfonyl-, carboxy-, Ci- ⁇ -alkyloxycarbonyl-, aminocarbonyl-, d- ⁇ -Alkylaminocarbonyl-, Di- (C ⁇ -5 -alkyl) -aminocarbonyl-, C 3-6 -Cycloalkyleniminocarbonyl-, aminosulfony
  • a phenyl, heteroaryl, phenyl-C ⁇ -5 -alkyl- or Heferoaryl- d- ⁇ -alkyl group which in the phenyl or heteroaryl part optionally one to three times selected by the same or different substituents from the group consisting of halogen atoms, C ⁇ - 5 -Alkyl-, di- (C ⁇ -5 -alkyl) -amino-, hydroxy-, -C ⁇ -5 -alkyloxy-, mono-, di- or trifluoromethoxy, carboxy and C ⁇ -5 -alkyloxycarbonyl groups can be substituted,
  • a 3- to 7-membered cycloalkyl, cycloalkyleneimino, cycloalkyl, Ci- ⁇ -alkyl or cycloalkylenimino-d -3 -alkyl group in which in 4- to 7-membered cycles in the cyclic part a methylene group optionally by a -N (R 8c ) group, an oxygen or sulfur atom or an -S (O) - or -S (0) 2 - group can be replaced, or in the case of 4- to 7-membered cycles in the cyclic part two adjacent methylene groups together may optionally be replaced by a -C (0) N (R 8b ) - or -S (0) 2 N (R 8b ) group, or in the case of 6- to 7-membered cycles in the cyclic part three adjacent methylene groups together optionally with a substituted -OC (0) N (R 8b ) - or -N (R 8b ) C (0) N (
  • Cycloalkylenimino-, Cycloalkyl-d- ⁇ -alkyl- or Cycloalkylenimino-C ⁇ -3 -alkyl group on one or two -CH 2 - groups can be substituted by one or two C ⁇ -3 alkyl groups, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3 -s-cycloalkyl or C 3-8 -cycloalkenyl group, one C3-8-cycloalkyl or C 4 -8-cycloalkenyl group on one single carbon atom by a C 2 alkylene group ⁇ , or simultaneously at two different carbon atoms by a C ⁇ - alkylene group to form a corresponding spirocyclic or a bridged bicyclic system may be substituted, wherein one of the methylene groups of a C 4- 8 cycloalkyl or C ⁇ - ⁇ - cycloalkenyl group or a corresponding spirocycle or a corresponding bridged bicyclus as described above can be replaced by an oxygen or sulfur atom or an -N (R 80 ) -, or a carbonyl, sulfinyl or sulfonyl group, and / or two directly adjacent methylene groups of a C 4-8
  • Cycioalkyl group together by a -OC (0) N (R 8b ) -, - N (R 8b ) C (0) N (R 8b ) - or -N (R 8b ) S (0) 2 N (R 8b ) - Group can be replaced
  • C 3-6 -cycloalkyleniminocarbonyl-, aminosulfonyl-, d- 5 -alkylaminosulfonyl-, di- (C ⁇ -5 -alkyl) -aminosulfonyl-, C 3-6 -cycloalkyleniminosulfonyl groups may be substituted, and 1 to 2 carbon atoms of a C 4-8 cycloalkenyl group which are not bonded to another carbon atom by a double bond, optionally independently of one another by one or two fluorine atoms or a hydroxy, C ⁇ -5 alkyloxy,
  • C ⁇ -5 -Alkylcarbonyloxy-, C ⁇ - 5 -Alkylsulfanyl-, C 1-5 -Alkylsulfonyl-, Amino-, C ⁇ -5-Alkylamino-, Di- (C ⁇ -5 -alkyl) -amino-, d- ⁇ -Alkylcarbonylamino -, -C ⁇ -5 -Alkylsulfonylamino-, ⁇ / - (C ⁇ -5 -Alkylsulfonyl) -C ⁇ -5 -alkylamino- or C 3-6 -cycloalkylcarbonylamino groups may be substituted,
  • the 6-membered heteroaryl group has one, two or three nitrogen atoms and the 5-membered heteroaryl group has an imino group which is optionally substituted by a C -3 alkyl, phenyl or phenyl-C -3 alkyl group, an oxygen or sulfur atom or an optionally by a C ⁇ - alkyl, phenyl, amino-C 2 - 3 alkyl, C ⁇ -3 alkylamino-C2-3-alkyl, di- (C ⁇ -3-alkyl) amino-C 2 -3- alkyl, a C 3 . 6 - Cycloalkylenimino-C 3 alkyl or phenyl-C.
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups contained in the definitions mentioned above have more than two carbon atoms Unless stated otherwise, may be straight-chain or branched and the alkyl groups in the above-mentioned dialkylated radicals, for example the dialkylamino groups, may be the same or different,
  • Examples of monocyclic heteroaryl groups are the pyridyl, ⁇ / -oxy-pyridyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, [1, 2,3] triazinyl, [1, 3,5] triazinyl, [ 1, 2,4] triazinyl, pyrrolyl, imidazolyl, [1, 2,4] triazolyl,
  • bicyclic heteroaryl groups are the benzimidazolyl, benzofuranyl, benzo [c] furanyl, benzothiophenyl, benzo [c] thiophenyl, benzothiazolyl, benzo [c] isothiazolyl, benzo [c / jisothiazolyl, benzooxazolyl, c] isoxazolyl-, benzo [e /] isoxazo!
  • yl- benzo [1, 2.5] oxadiazolyI-, benzo [1, 2.5] thiadiazolyl-, benzo [1, 2.3] thiadiazolyl-, benzo [ c /] [1, 2,3] triazinyl, benzo [1, 2,4] triazinyl, benzotriazolyl, cinnolinyl, quinolinyl, ⁇ / -oxy-quinolinyl, isoquinolinyl, quinazolinyl, ⁇ / - Oxy-quinazolinyl, quinoxalinyl, phthalazinyl, indolyl, isoindolyl or 1-oxa-2,3-diaza-indenyl group.
  • Examples of the d- 6 alkyl groups mentioned above in the definitions are the methyl, ethyl, 1-propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1-pentyl, , 2-pentyl, 3-pentyl, neo-pentyl, 3-methyl-2-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 3-methyl-2-pentyl, 4- Methyl 2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,2-dimethyl-3-butyl or 2,3-dimethyl-2-butyl group.
  • Examples of the d- ⁇ -alkyloxy groups mentioned above in the definitions are the methyloxy, ethyloxy, 1-propyloxy, 2-propyloxy, n-butyloxy, sec-butyloxy, fert-butyloxy, 1-pentyloxy , 2-pentoxy, 3-pentyloxy or neo-pentyloxy group.
  • C 2 - 6 alkenyl groups are ethenyl, 1-propen-1-yl, 2-propen-1-yl, 1-butene-1-yl, 2-butene 1-yl, 3-buten-1-yl, 1-pentene-1-yl, 2-pentene-1-yl, 3-pentene-1-yl, 4-pentene-1-yl, 1-hexen-1-yl, 2-hexen-1-yl, 3-hexen-1-yl, 4-hexen-1-yl, 5-hexen-1-yl, but-1-ene -2-yl, but-2-en-2-yl, but-1-en-3-yl, 2-methyl-prop-2-en-1-yl, pent-1-en-2 -yl-, Pent-2-en-2-yl-, Pent-3-en-2-yl-, Pent-4-en-2-yl-, Pent-1-en-3-yl-, Pent- 2-
  • C 2 - 6 alkynyl groups are ethynyl, 1 -Propinyl-, 2-propynyl, 1-butyn-1 -yl, 1-butyn-3-yl, 2-butyne -1-yl-, 3-butyn-1-yl-, 1-pentyn-1-yl-, 1-pentyn-3-yl-, 1-pentyn-4-yl-, 2-pentyn-1-yl- , 2-pentyn-3-yl-, 3-pentyn-1-yl-, 4-pentyn-1-yl-, 2-methyl-1-butyn-4-yl-, 3-methyl-1-butyn-1 -yl-, 3-Methyl-1-butin-3-yl-, 1-Hexin-1-yl-, 2-Hexin-1-yl-, 3-Hexin-1-yl-, 4-Hexin-1- yl-, 5-hex
  • a group which can be converted into a carboxy group in vivo is, for example, a carboxy group esterified with an alcohol, in which the alcoholic part preferably a C ⁇ - 6 alkanol, a phenyl-d -3- alkanol, a C 3 -g cycloalkanol, a C 5-7 cycloalkenol, a C 3-5 alkenol, a phenyl C 3 - ⁇ -alkenol, a C 3 - 5 -alkinol or phenyl-C 3-5 -alkinol with the proviso that no bond to the oxygen atom originates from a carbon atom which carries a double or triple bond, a C 3-8 -cycloalkyl- C ⁇ -3- alkanol or an alcohol of the formula
  • R 9 is a C 1-8 alkyl, C 5 - 7 cycloalkyl, phenyl or phenyl -C -3 alkyl group,
  • R 10 is a hydrogen atom, a C -3 alkyl, C 5 -7 cycloalkyl or phenyl group and
  • R 11 represents a hydrogen atom or a C -3 alkyl group
  • Preferred residues which can be split off from a carboxy group in vivo are a d- ⁇ -alkoxy group such as the methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, n-pentyloxy, n-hexyloxy or cyclohexyloxy group or a phenyl -C ⁇ -3 -alkoxy group as the benzyloxy group into consideration.
  • a group which can be converted into a hydroxyl group in vivo is, for example, a hydroxyl group esterified with a carboxylic acid, in which the carboxylic acid part is preferably a C 1 -C 6 -alkanoic acid, a phenyl C 3 -C 3 -alkanoic acid, a C 3-9 cycloalkyl carboxylic acid, a C ⁇ - 7- cycloalkenecarboxylic acid, a C 3-7 -alkenoic acid, a phenyl-
  • a C 7 -acyl group such as the formyl, acetyl, n-propionyl, isopropionyl, n-propanoyl, n-butanoyl, n-pentanoyl, n-hexanoyl are preferred residues which can be split off from a hydroxyl group in vivo - or cyclohexylcarbonyl group or a benzoyl group and also a methoxyacetyl, 1-methoxypropionyl, 2-methoxypropionyl or 2-methoxyethoxyacetyl group.
  • Those compounds of the general formula I in which A, R 4 and / or R 5 contain a group which can be converted into a carboxy or hydroxyl group in vivo are prodrugs for those compounds of the general formula I in which A, R 4 and / or R 5 contains a carboxy or hydroxyl group.
  • a 10th embodiment of the present invention comprises those compounds of the general formula I in which
  • A is a radical of the general formula
  • R 8a each independently of one another is a hydrogen or fluorine atom or a Ci- ⁇ -alkyl, hydroxy, hydroxy-d -5 -alkyl-, C ⁇ -5 -alkoxy-, d- 5 -alkoxy-C ⁇ - 5 -alkyl- , Amino-, C ⁇ -5 -alkylamino-, di- (C ⁇ - ⁇ -alkyl) -amino-, amino-C ⁇ -5 -alkyl-, d- ⁇ -alkylamino-Ci- ⁇ -alkyl-, di- (C ⁇ -5 -alkyl) -amino-C ⁇ -5 -alkyl-, aminocarbonyl-, C ⁇ -5 -alkylaminocarbonyl-, di- (C ⁇ -5 -Alkyl) -aminocarbonyl- or Ci- ⁇ -alkylcarbonylamino group, with those mentioned above substituted 5- to 7-membered
  • R 8b each independently represents a hydrogen atom or a d- 5 alkyl group
  • R 8c each independently represent a hydrogen atom, a C ⁇ -5 alkyl, Ci. ⁇ -alkylcarbonyl-, C ⁇ -5 -alkyloxycarbonyl- or d -5 -alkylisulfonyl group,
  • X represents an oxygen atom or an -NR group
  • X 4 represents an oxygen or sulfur atom or an -NR group
  • R 1 is a fluorine, chlorine, bromine or iodine atom, a C -3 alkyl or d 3 alkoxy group, the hydrogen atoms of the C 1-3 alkyl or C 3 -3 alkoxy group can optionally be wholly or partly replaced by fluorine atoms, a C 2-3 alkenyl, C 2-3 alkynyl, nitrile, nitro or amino group means
  • R 2 represents a hydrogen or halogen atom or a C 3 -3 alkyl group
  • R 3 represents a hydrogen atom or a C 1-3 alkyl group
  • R 4 and R 5 are each independently a hydrogen atom, a C 2-6 alkenyl or C 2- 6-alkynyl group, a linear or branched C ⁇ -6 alkyl group, wherein the hydrogen atoms of the straight-chain or branched C 6 alkyl group optionally can be replaced in whole or in part by fluorine atoms, and which may be replaced by a C 3-5 cycloalkyl group, a nitrile, hydroxyl, a C ⁇ - 5 alkyloxy group, where the hydrogen atoms of the Ci-s-alkyloxy group may be wholly or partly by fluorine atoms can be replaced, an allyloxy, propargyloxy, benzyloxy, C ⁇ - alkylcarbonyloxy, d- ⁇ -Aikyloxycarbonyloxy-, carboxy-d- ⁇ -alkyloxy-, C ⁇ .
  • a phenyl, heteroaryl, phenyl-C 1-5 -alkyl or heteroaryl-Ci- ⁇ -alkyl group which in the phenyl or heteroaryl part is optionally selected one to three times by identical or different substituents selected from the group consisting of halogen atoms, i.e. - ⁇ -alkyl-, di- (C ⁇ -5 -alkyl) -amino-, hydroxy-, C ⁇ _ 5 -alkyloxy, mono-, di- or trifluoromethoxy, carboxy and Ci- ⁇ - alkyloxycarbonyl groups can be substituted,
  • a 3- to 7-membered cycloalkyl, cycloalkylenimino, cycloalkyl -C 5 -5 alkyl or cycloalkylenimino -C 3 -3 alkyl group in which in 4- to 7-membered cycles in the cyclic part a methylene group optionally by a -N (R 8c ) group, an oxygen or sulfur atom or an -S (O) - or -S (0) 2 - group can be replaced, or in the case of 4- to 7-membered cycles in the cyclic part two adjacent methylene groups together may optionally be replaced by a -C (0) N (R 8b ) - or -S (0) 2 N (R 8b ) group, or in the case of 6- to 7-membered cycles in the cyclic part three adjacent methylene groups together optionally with a substituted -OC (0) N (R 8b ) - or -N (R 8b ) C (0) N (
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3-8 cycloalkyl or C 3-8 cycloalkenyl form, wherein a C 3-8 cycloalkyl or C 4-8 cycloalkenyl group of a single carbon atom can be substituted by a C 2 - ⁇ alkylene group or simultaneously on two different carbon atoms by a C ⁇ - 4 alkylene group to form a corresponding spirocycle or a bridged bicyclus, one of the methylene groups being a C 4 - 8 cycloalkyl group or C ⁇ - 8 - cycloalkenyl group or a corresponding spirocycle or a corresponding bridged bicyclus as described above can be replaced by an oxygen or sulfur atom or an -N (R 8c ) -, or a carbonyl, sulfinyl or sulfonyl group and / or two directly adjacent methylene groups of a C
  • Ci. ⁇ alkylaminosulfonyl, di (C ⁇ -5 alkyl) -aminosulfonyl-, C 3 - 6 -Cycloalkyleniminosulfonyl phenomenon may be substituted
  • a C those composed of R 4 and R 5 are formed 3-8 -cycloalkyl or C 3 -8-cycloalkenyl group or a as described above, a corresponding spirocyclic or a corresponding bridged bicyclic system, in which two heteroatoms in the cycle from the group oxygen and nitrogen are separated from one another by exactly one optionally substituted -CH group, and / or in which one or both methylene groups of the cycle which are directly connected to the carbon atom on which the radicals R 4 and R 5 are attached, are replaced by a hetero atom from the group oxygen, nitrogen and sulfur, and / or in which a substituent bound to the cyclic group, which is characterized in that a hetero atom from the group oxygen, nitrogen, sulfur and halogen atom directly attached the cyclic group is bound by another heteroatom from the group of oxygen, nitrogen and sulfur, with the exception of the sulfone group, by exactly one, if necessary all substituted, methylene group is separated, and
  • R 6 represents a fluorine, chlorine, bromine or iodine atom, a nitrile group, a C -3 alkyl group, or a C 3 -3 alkoxy group, the hydrogen atoms of the d -3 alkyl or d -3 alkoxy group entirely or can be partially replaced by fluorine atoms,
  • R 7 is, independently of one another, a C 3 alkyl, where the hydrogen atoms can optionally be replaced in whole or in part by fluorine atoms, hydroxy-, d -3 -alkyloxy-, where the hydrogen atoms can be replaced in whole or in part by fluorine atoms, amino , d- 3 -Alkyl ⁇ ino-, di- (C ⁇ -3 -alkyl) -amino-, C 3-6 -cycloalkylenimino-, carboxy-, nitrile-, d- 3 -alkoxycarbonyl-, aminocarbonyl-, C ⁇ -3 - Represents alkylaminocarbonyl or a di (C ⁇ -3-alkyl) aminocarbonyl group,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a C -3 alkyl, phenyl or phenyl C 3 -3 alkyl group, an oxygen or sulfur atom or one optionally by a C 1-3 alkyl, phenyl, amino-C 2-3 alkyl, -C-3-alkylamino-C 2-3 alkyl, di- (C ⁇ -3-alkyl) amino -C 2 - 3 -alkyl-, a C 3-6 - cycloalkylenimino-C ⁇ -3 -alkyl or phenyl-C ⁇ -3 -alkyl group substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom or an optionally by a C
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and which have more than two carbon atoms, unless stated otherwise, can be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, can be the same or different,
  • An 11th embodiment of the present invention comprises those compounds of the general formula I in which
  • A is a radical of the general formula
  • n 1 or 2
  • R 8a each independently represent a hydrogen or fluorine atom or an alkyl C 1-5 alkyl, hydroxy, hydroxy-C ⁇ -5, C ⁇ -5 alkoxy, C ⁇ -5-alkoxy-5 C ⁇ - alkyl -, Amino-, C ⁇ - 5 -alkylamino-, di- (C ⁇ - 5 -alkyl) -amino-, amino-C ⁇ -5 -alkyl-, C ⁇ - 5 -alkylamino-C ⁇ -5 -alkyl-, Di- ( d-5-alkyl) amino-C 5 alkyl, aminocarbonyl, C -5 alkylaminocarbonyl, di (C -5 alkyl) aminocarbonyl or d 5 alkylcarbonylamino group, where in the case of the above-mentioned substituted 5- to 7-membered radicals A, the heteroatoms F, O or N which are optionally introduced with R 8a as substituents are not separated from a hetero
  • R 8b each independently represents a hydrogen atom or a Ci-s-alkyl group
  • R 8c each independently represent a hydrogen atom, a C ⁇ -5 alkyl, C ⁇ -5-alkylcarbonyl, G- ⁇ -5-alkyloxycarbonyl or C ⁇ -5-alkylsulphonyl group means
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen atom or a -NR group 8o
  • R is a fluorine, chlorine, bromine or iodine atom, a C ⁇ -3 alkyl or C ⁇ -3 alkoxy group, the hydrogen atoms of the C ⁇ -3 alkyl or C ⁇ -3 alkoxy group optionally being wholly or partly replaced by fluorine atoms can be, or means a nitrile group,
  • R 2 represents a hydrogen or halogen atom or a methyl group
  • R 3 represents a hydrogen atom or a methyl group
  • R 4 is a C 2-6 -alkenyl or C 2 - 6 alkynyl group, a straight-chain or branched C ⁇ -6 alkyl group, where the hydrogen atoms of the straight-chain or branched C ⁇ -6 alkyl group may optionally be wholly or partly replaced by fluorine atoms, and which may optionally be replaced by a C 3-5 - cycloalkyl group, a nitrile, hydroxy , a C 1-5 alkyloxy group, where the hydrogen atoms of the C ⁇ -5 alkyloxy group can optionally be replaced in whole or in part by fluorine atoms, a benzyloxy, C ⁇ - 5 alkylcarbonyloxy, C- ⁇ - 5 alkyloxycarbonyloxy, carboxy Ci.s-aikyloxy-, C ⁇ -5 -AlkyloxycarbonyI-d -5 -alkyloxy-, C ⁇ -5 -alkylsulfanyl-,
  • a phenyl, heteroaryl, phenyl-C ⁇ -5 -alkyl or heteroaryl-d- 5 -alkyl group which in the phenyl or heteroaryl part optionally one to three times selected by the same or different substituents from the group consisting of halogen atoms, C ⁇ - 5 -alkyl-, di- (C ⁇ -5 -alkyl) -amino-, hydroxy-, Ci-s-alkyloxy, mono-, di- or trifluoromethoxy, carboxy and Ci.s-alkyloxycarbonyl groups can be substituted,
  • 3 -alkyl group in the 4- to 7-membered cycles in the cyclic part a methylene group, optionally by an -N (R 8o ) group Oxygen or sulfur atom or an -S (O) - or -S (0) 2 group can be replaced, or in which, in the case of 4- to 7-membered cycles in the cyclic part, two adjacent methylene groups together, if appropriate, by a -C (0 ) N (R 8b ) - or -S (0) 2 N (R 8b ) group can be replaced, or
  • a straight-chain or branched C ⁇ -6 alkyl group where the hydrogen atoms of the straight-chain or branched C ⁇ - 6 alkyl group can optionally be wholly or partly replaced by fluorine atoms, and optionally by a C ⁇ - 5 alkyloxy group, the hydrogen atoms of the d- 5th -Alkyloxy group, if appropriate, in whole or in part Fluorine atoms can be replaced, can be substituted, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3-8 -CycloalkyI- or C 3-8 cycloalkenyl form, wherein a C 3-8 -CycIoalkyl- or C 4-8 cycloalkenyl group of a single carbon atom can be substituted by a C 2-5 alkylene group or at the same time on two different carbon atoms by a C ⁇ -4 alkylene group to form a corresponding spirocycle or a bridged bicyclus, one of the methylene groups of a C 4-8 cycloalkyl- or C 5-8 - cycloalkenyl group or a corresponding spirocycle or a corresponding bridged bicyclus as described above can be replaced by an oxygen or sulfur atom or an -N (R 8c ) -, or a carbonyl or sulfonyl group, and / or two directly adjacent methylene groups of a C 4-8 cycl
  • R 6 represents a fluorine, chlorine, bromine or iodine atom, a nitrile group, a C ⁇ -3 alkyl group, or a C ⁇ -3 alkoxy group, the hydrogen atoms of the C ⁇ -3 alkyl or C ⁇ - 3 alkoxy group optionally can be replaced in whole or in part by fluorine atoms,
  • R 7 is, independently of one another, a C 3 alkyl, where the hydrogen atoms can optionally be replaced in whole or in part by fluorine atoms, hydroxy-, d -3 -alkyloxy-, where the hydrogen atoms can be replaced in whole or in part by fluorine atoms, amino , C ⁇ - 3 -alkylamino-, di- (C ⁇ -3 -alkyl) -amino-, C 3-6 -cycloalkylenimino-, carboxy-, nitrile-, C ⁇ - 3 -alkoxycarbonyl-, aminocarbonyl-, C ⁇ -3 - Represents alkylaminocarbonyl or a di (C ⁇ -3 alkyl) aminocarbonyl group,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a d- 3 -alkyl, phenyl or phenyl-C ⁇ -3 -alkyl group, an oxygen or sulfur atom or an optionally by a C ⁇ - 3 alkyl, phenyl, amino-C 2-3 -alkyl-, C ⁇ - 3 -alkylamino-C 2 - 3 -alkyl-, di- (C ⁇ - 3 -alkyl) -amino-C 2 - 3 -alkyl-, a C 3-6 - cycloalkylenimino-C ⁇ -3 - aIkyl- or phenyl-C ⁇ -3 -alkyl group substituted im
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, may be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, contained in the definitions mentioned above , can be the same or different,
  • a 12th embodiment of the present invention includes those Compounds of the general formula I in which
  • A is a radical of the general formula
  • n 1 or 2
  • R 8a each independently of one another represents a hydrogen or fluorine atom or a C 3 alkyl, hydroxy, hydroxy C 3 alkyl, C 3 alkoxy, C 3 alkoxy C 3 C 3 alkyl , Amino-, C ⁇ -3- alkylamino-, di- (C ⁇ -3 -alkyl) -amino-, amino-C ⁇ -3 -alkyl-, C ⁇ -3 -alkylamino-C ⁇ -3 -alkyl-, Di- (C ⁇ - 3 -Alkyl) -amino-C ⁇ - 3 -alkyl-, aminocarbonyl-, C ⁇ -3 -alkylaminocarbonyl-, di- (C ⁇ -3 -alkyl) -aminocarbonyl- or C ⁇ -3- alkylcarbonylamino group, with the above substituted 5- to 7-membered radicals A, the heteroatoms F, Cl, Br, I, O or N
  • R 8b each independently represents a hydrogen atom or a C 3 -3 alkyl group
  • X 1 is a carbonyl, thiocarbonyl
  • C NR 8c -
  • C N-OR 8c -
  • C N-N0 2 -
  • C N-CN or sulfonyl group
  • R 8c each independently represents a hydrogen atom, a C 3 alkyl, C 3 alkyl carbonyl, C 4 alkyloxycarbonyl or C 3 alkyl sulfonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen atom or an -NR 8c group
  • R 1 is a fluorine, chlorine, bromine or iodine atom, a C -3 alkyl or a C 3 alkoxy group, the hydrogen atoms of the d -3 alkyl or d 3 alkoxy group optionally in whole or in part can be replaced by fluorine atoms,
  • R 2 represents a hydrogen or halogen atom or a methyl group
  • R 3 represents a hydrogen atom
  • R 4 is a C 2-4 alkenyl or C 2-4 alkynyl group, a straight-chain or branched C 4 alkyl group, it being possible for the hydrogen atoms of the straight or branched C 4 alkyl group to be replaced in whole or in part by fluorine atoms, and which may be replaced by a C 3-5 - cycloalkyl group, a nitrile, hydroxyl, a C ⁇ -3 -alkyloxy group, where the hydrogen atoms of the C ⁇ -3 -alkyloxy group may be wholly or partly replaced by fluorine atoms, a benzyloxy, C ⁇ -3 -alkylcarbonyloxy-, -C ⁇ -3 -alkyloxycarbonyl-C ⁇ -3 -alkyIoxy-, C ⁇ -3 -alkyloxycarbonyl-, aminocarbonyl-, C ⁇ -3 -alkylaminocarbonyl-, di- (C ⁇ -3 -
  • 3 -alkylamino group can be substituted, a phenyl, heteroaryl, phenyl -C 3 -3 -alkyl or heteroaryl -C 3 -3 alkyl group, which in the phenyl or heteroaryl part optionally one to three times selected from the same or different substituents Group consisting of halogen atoms, C ⁇ -3 alkyl, di (C ⁇ -3 alkyl) amino, hydroxy, C ⁇ -3 alkyloxy, mono-, di- or trifluoromethoxy, carboxy and C ⁇ -3 Alkyloxycarbonyl groups can be substituted,
  • R 5 is a hydrogen atom, a C 2 - 4 alkenyl or C 2 - alkynyl group, a straight-chain or branched C 4 -4 -alkyl group, the hydrogen atoms of the straight-chain or branched C 4 -4 -alkyl group optionally being completely or partially replaced by fluorine atoms can, and which can optionally be substituted by a C ⁇ -3 alkyloxy group, where the hydrogen atoms of the C ⁇ - 3 alkyloxy group may be replaced in whole or in part by fluorine atoms, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached, a C 3 - 8 cycloalkyl or form C3- 8 cycloalkenyl group, a C 3 -8-cycloalkyl or C 4 -8 cycloalkenyl group at a single carbon atom by a C 2-5 alkylene group or simultaneously on two different carbon atoms can be substituted by a C 4 alkylene group to form a corresponding spirocycle or a bridged bicyclic group,
  • Cycloalkenyl group or a corresponding spirocycle or a corresponding bridged bicyclus as described above can be replaced by an oxygen or sulfur atom or a sulfonyl or -N (R 8c ) group, and / or
  • two directly adjacent methylene groups of a C -8- cycloalkyl group can be replaced together by a -C (0) N (R 8b ) -, - C (0) 0- or -S (0) 2 N (R 8b ) group, and or
  • R 6 represents a fluorine, chlorine, bromine or iodine atom, a methyl group or a methoxy group, it being possible for the hydrogen atoms of the methyl or methoxy group to be replaced in whole or in part by fluorine atoms,
  • R 7 independently of one another is a C 3 alkyl, where the hydrogen atoms can optionally be replaced in whole or in part by fluorine atoms, hydroxy, C 3 -3 alkyloxy, where the hydrogen atoms can be replaced in whole or in part by fluorine atoms, amino, C ⁇ -3 -Alkylamino-, di- (C ⁇ -3 -alkyl) -amino-, C 3 - 6 -cycloalkylenimino-, carboxy-, nitrile-, C ⁇ - 3 -alkoxycarbonyl-, aminocarbonyl-, C ⁇ - 3 -alkylaminocarbonyl - or represents a di (C ⁇ -3 alkyl) aminocarbonyl group,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a C 3 alkyl, phenyl or phenyl-d-3-alkyl group, an oxygen or sulfur atom or optionally substituted by a C ⁇ -3 alkyl, phenyl, amino-C 2 -3-alkyl-, C ⁇ - 3 -alkylamino-C 2 - 3 -alkyl, di- (3 C ⁇ - alkyl) amino C 2 - 3 alkyl, a C 3-6 - cycloalkylenimino -C 3 -3 alkyl or phenyl C 3 -3 alkyl group substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom or an optionally by a
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkenyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, may be straight-chain or branched and the alkyl groups in the abovementioned dialkylated radicals, for example the dialkylamino groups, contained in the definitions mentioned above , can be the same or different,
  • a 13th embodiment of the present invention comprises those compounds of the general formula I in which
  • A is a radical of the general formula
  • n 1 or 2
  • R 8b each independently represents a hydrogen atom or a C ⁇ -3 alkyl group means
  • R 8c each independently represents a hydrogen atom, a C 3 alkyl, C 3 alkylcarbonyl or a C 4 alkyloxycarbonyl group,
  • X 2 is an oxygen atom or an -NR 8 group
  • X represents an oxygen atom or an -NR group
  • R 1 represents a fluorine, chlorine, bromine or iodine atom, a methyl or a methoxy group, where the hydrogen atoms of the methyl or methoxy group can optionally be completely or partially replaced by fluorine atoms,
  • R 2 represents a hydrogen or fluorine atom or a methyl group
  • R 3 represents a hydrogen atom
  • R 4 is a C - alkenyl or C 2 - 4 alkynyl group, a straight-chain or branched C ⁇ -4 alkyl group, where the hydrogen atoms of the straight-chain or branched C ⁇ -4 alkyl group can optionally be wholly or partly replaced by fluorine atoms, and the optionally by a nitrile, hydroxyl, ad- 3 -alkyloxy group, where the hydrogen atoms of the d- 3 -alkyloxy group can optionally be wholly or partly replaced by fluorine atoms, a benzyloxy-, -C-- 3- alkylcarbonyloxy- d-3-alkyloxycarbonyl-, aminocarbonyl-, C ⁇ - 3 -alkylaminocarbonyl-, di- (C ⁇ -3 -alkyl) -aminocarbonyl-, C 3-6 -cycloalkyleniminocarbonyl-, aminosulfonyl-
  • R 5 is a hydrogen atom, a straight-chain or branched C ⁇ . 4 -alkyl group, where the hydrogen atoms of the straight-chain or branched C ⁇ - 4 alkyl group can optionally be replaced in whole or in part by fluorine atoms, and which may optionally be replaced by a C ⁇ -3 alkyloxy group, the hydrogen atoms in the C ⁇ -3 alkyloxy group optionally in whole or in part can be replaced by fluorine atoms, can be substituted, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached form a C3-s-cycloalkyl or C form -8 cycloalkenyl group, a C 3-8 cycloalkyl or C 4 -s-cycloalkenyl group at a single carbon atom by a C 2 - 5 alkylene group or simultaneously to different two carbon atoms can be substituted by a C 4 alkylene group to form a corresponding spirocycle or a bridged bicyclic group,
  • Cycloalkenyl group or a corresponding spirocycle or a corresponding bridged bicyclus as described above can be replaced by an oxygen or sulfur atom or a sulfonyl or -N (R 8c ) group, and / or
  • R 6 represents a fluorine, chlorine, bromine or iodine atom, a methyl group or a methoxy group, it being possible for the hydrogen atoms of the methyl or methoxy group to be replaced in whole or in part by fluorine atoms,
  • R 7 is, independently of one another, a C 3 alkyl, where the hydrogen atoms can optionally be wholly or partly replaced by fluorine atoms, hydroxy, C 3 -3 alkyloxy, where the hydrogen atoms can be wholly or partly replaced by fluorine atoms, amino , C ⁇ - 3 -alkylamino-, di- (C ⁇ -3 -alkyl) -amino-, C 3 -6-cycloalkylenimino-, carboxy-, nitrile, C ⁇ - 3 -alkoxycarbonyl-, aminocarbonyl-, C ⁇ -3 - Represents alkylaminocarbonyl or a di (C ⁇ -3 alkyl) aminocarbonyl group,
  • heteroaryl group mentioned above in the definitions is to be understood as a monocyclic 5- or 6-membered heteroaryl group, the 6-membered heteroaryl group being one, two or three nitrogen atoms and the 5-membered heteroaryl group an imino group optionally substituted by a d- 3 alkyl, phenyl or phenyl d -3 alkyl group, an oxygen or sulfur atom or an optionally by a C -3 alkyl, phenyl, amino C 2-3 -alkyl-, C ⁇ -3 -alkylamino-C 2-3 -alkyl-, di- (C ⁇ -3 -alkyl) -amino-C 2-3 -alkyl-, a C 3-6 - cycloalkylenimino-C ⁇ -3- contains alkyl or phenyl-C ⁇ -3 -alkyl group substituted imino group or an oxygen or sulfur atom and additionally a nitrogen atom
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl, alkynyl and alkoxy groups which have more than two carbon atoms and, unless stated otherwise, can be straight-chain or branched, and the alkyl groups in the above-mentioned dialkylated radicals, for example the dialkylamino groups, are identical or are contained in the abovementioned definitions can be different
  • a 14th embodiment of the present invention comprises those compounds of the general formula I in which
  • A is a radical of the general formula (R - w - ⁇ R * V- .- (R8 V- N - x , -, or ° means
  • n 1 or 2
  • R 8a each independently of one another is a hydrogen or fluorine atom or a C 3 -3 alkyl, hydroxy, hydroxy C 3 -3 alkyl, d -3 alkoxy, C 3 -3 alkoxy C 1. 3 -alkyl-, amino-, C ⁇ -3 -alkylamino-, di- (C ⁇ - 3 -alkyl) -amino-, amino-d -3 -alkyl-, C ⁇ -3 -alkylamino-C ⁇ -3-alkyl-, Di- (-C -3 alkyl) amino -C 3 alkyl group means, in the case of the above-mentioned substituted 5- to 7-membered radicals A, the heteroatoms F, O or N optionally introduced with R 8a as substituents are not exactly a carbon atom is separated from a hetero atom from the group N, O, S,
  • R 8b represents a hydrogen atom or a C -3 alkyl group
  • R 8c each independently represents a hydrogen atom, a C 3 alkyl, C 3 alkylcarbonyl or a C 4 alkyloxycarbonyl group,
  • X 2 is an oxygen atom or an -NR 8b group
  • R 1 represents a fluorine, chlorine, bromine or iodine atom, a methyl or a methoxy group, where the hydrogen atoms of the methyl or methoxy group can optionally be completely or partially replaced by fluorine atoms,
  • R 2 represents a hydrogen or fluorine atom
  • R 3 represents a hydrogen atom
  • R 4 is a straight-chain or branched C -4 alkyl group, where the hydrogen atoms may optionally be replaced in whole or in part by fluorine atoms, and which may optionally be replaced by a hydroxy, a C 3 -3 alkyloxy group, the hydrogen atoms of the C 3 -3 alkyloxy group entirely or can be partially replaced by fluorine atoms, a benzyloxy, C ⁇ -3 alkylcarbonyloxy, C ⁇ -3 alkyloxycarbonyl, aminocarbonyl, C 1-3 alkylaminocarbonyl, di (C ⁇ -3 alkyl) aminocarbonyl, C 3-6 -Cycioalkyleniminocarbonyl-, aminosulfonyl-, C1-3-AI- kylaminosulfonyl-, di- (C ⁇ -3 -alkyl) -aminosulfonyl-, C 3-6 -cycloalkyleniminosulfonyl-, amino
  • R 5 is a hydrogen atom, a straight-chain or branched C -4 alkyl group, where the hydrogen atoms can optionally be replaced in whole or in part by fluorine atoms, and which may optionally be replaced by a d 3 -alkyloxy group, the hydrogen atoms in the C -3 alkyloxy group optionally being entirely or may be partially replaced by fluorine atoms, may be substituted, means, or
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3-7 cycloalkyl or C 4-7 cycloalkenyl group form, wherein a C 3-7 cycloalkyl or C4 7 cycloalkenyl group at a single carbon atom can be substituted by a C 2 - 5 alkylene group or at the same time on two different carbon atoms by a C ⁇ - 4 alkylene group to form a corresponding spirocycle or a bridged bicyclus, one of the methylene groups being a C 4 -7-cycloalkyl or C4-7 cycloalkenyl group or a corresponding spirocycle or a corresponding bridged bicyclus as described above can be replaced by an oxygen or sulfur atom or a sulfonyl or -N (R 8o ) group, and / or two directly adjacent methylene groups a C 4 - 7 cycloalkyl group together by a -C (0)
  • R 6 represents a chlorine or bromine atom
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl and alkoxy groups contained in the definitions mentioned above, which have more than two carbon atoms, unless stated otherwise, can be straight-chain or branched and the alkyl groups in the dialkylated radicals mentioned above, for example the dialkylamino groups, can be identical or different .
  • a 15th embodiment of the present invention comprises those compounds of the general formula I in which
  • A is a radical of the general formula
  • n 1 or 2
  • R 8a each independently of one another is a hydrogen or fluorine atom or a -C 3 alkyl, hydroxy, hydroxy C 3 -3 alkyl, C 3 alkoxy, d 3 alkoxy d 3 alkyl group , Amino-, C ⁇ -3 -alkylamino-, di- (C ⁇ -3 -alkyl) -amino-, amino-C ⁇ -3 -aikyl-, C ⁇ -3 -alkylamino-C ⁇ -3 -alkyl-, Di- (C ⁇ -3 -alkyl) -amino-C ⁇ -3 -alkyl group means, in the case of the above-mentioned substituted 5- to 7-membered radicals A, the heteroatoms F, O or N, optionally introduced with R 8a , are not replaced by exactly one carbon atom of one Heteroatoms are separated from the group N, O, S,
  • R 8b represents a hydrogen atom or a C -3 alkyl group
  • R 8c represents a hydrogen atom, a C -3 alkyl, d -3 alkyl carbonyl, or a C 4 alkyloxycarbonyl group
  • X 2 is an oxygen atom or an -NR 8b group
  • X 4 represents an oxygen atom or a -NR group 8o
  • R 1 represents a chlorine or bromine atom, a methyl, trifluoromethyl or a methoxy group
  • R -.2 represents a hydrogen or fluorine atom
  • R D3 represents a hydrogen atom
  • R 4 is a methyl group which may optionally be substituted by a hydroxy, methoxy, benzyloxy, methoxycarbonyl or pyridin-4-yl group, or a 1-methyl-pyrazin-3-yl, phenyl, pyridin-3- yl or pyrazin-2-yl group means
  • R 5 represents a hydrogen atom or a methyl group
  • R 4 and R 5 together with the carbon atom to which they are attached form a C 3 -6-cycloalkyl or C 5 -6-cycloalkenyl group, a C 5-6 -cycloalkyl or Cs- ⁇ -cycloalkenyl group being present simultaneously two different carbon atoms may be substituted by a C ⁇ -2 alkylene group to form a bridged bicyclic group, wherein one of the methylene groups of a C 4 -6 cycloalkyl or C 5 - 6 - cycloalkenyl group or a as described above, corresponding bridged bicyclic group by a oxygen atom or a -N (R 8c) may be replaced group, with the proviso that those composed of R 4 and R 5 are formed C3- 6 cycloalkyl or cycloalkenyl group or a Cs ⁇ as described above, corresponding bridged bicyclus, in which one methylene group of the cycle, which is directly connected to the carbon atom to which
  • R 6 represents a chlorine or bromine atom
  • halogen atom means an atom from the group fluorine, chlorine, bromine and iodine
  • alkyl and alkoxy groups contained in the definitions mentioned above, which have more than two carbon atoms, unless stated otherwise, can be straight-chain or branched and the alkyl groups in the dialkylated radicals mentioned above, for example the dialkylamino groups, can be identical or different .
  • a 16th embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14 and 15 in which R 4 and R 5 are not hydrogen.
  • a 17th embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14, 15 and 16, in which R 4 and R 5 together with the carbon atom to which they are attached , form a cyclic group each defined as in the 9th, 10th, 11th, 12th, 13th, 14th or 15th embodiment.
  • An 18th embodiment of the present invention comprises those compounds of general formula I according to embodiments 9, 10, 11, 12, 13, 14, 15, 16 and 17, in which R 4 and R 5 together with the carbon atom to which they are attached are bound to form a cyclic group, which is in each case as defined in the 9th, 10th, 11th, 12th, 13th, 14th or 15th embodiment, where the cyclic group or the corresponding bridged bicyclus or the spirocycle in accordance with the above-mentioned requirements
  • Methylene group is replaced by an oxygen atom or an N (R 8c ) group.
  • a 19th embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18, in which R 4 and R 5 together with the carbon atom to which they are attached form a cyclic group which, as described in the 9th, 10th, 11th, 12th, 13th, 14th or 15th embodiment, does not represent a bridged bicyclus or a spirocyclic group by appropriate substitution.
  • a 20th embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18, in which R 4 and R 5 together with the The carbon atom to which they are attached form a cyclic group which, as described in the 9th, 10th, 11th, 12th, 13th, 14th or 15th embodiment, represents a bridged bicyclic or a spirocyclic group by appropriate substitution ,
  • a 21st embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19, in which R 4 and R 5 together with the carbon atom to which they are attached, a cyclic group
  • a 22nd embodiment of the present invention includes those
  • a 23rd embodiment of the present invention includes those
  • a 25th embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23, in which the rest A the group
  • a 26th embodiment of the present invention includes those
  • a 27th embodiment of the present invention comprises those compounds of the general formula I corresponding to embodiments 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 and 26 in which R 6 represents a bromine atom.
  • a 28th embodiment of the present invention includes those Compounds of general formula I according to embodiments 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 and 26, in which R 6 is a chlorine atom means.
  • the compounds of the general formula I are obtained by processes known per se, for example by the following processes:
  • the reduction of the nitro group is advantageously carried out, for example, in a solvent or solvent mixture such as water, aqueous ammonium chloride solution, hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, acetic anhydride with base metals such as iron, zinc, tin or sulfur compounds such as ammonium sulfide, sodium sulfide or Sodium dithionite or by catalytic hydrogenation with hydrogen, for example under a pressure between 0.5 and 100 bar, but preferably between 1 and 50 bar, or with hydrazine as a reducing agent, advantageously in the presence of a catalyst such as Raney nickel, palladium-carbon, platinum oxide, platinum on mineral fiber or rhodium, or with complex hydrides such as lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, diisobutyl aluminum hydride, advantageously in a solvent or solvent mixture such as water, methanol, ethanol, isopropanol
  • a ' represents a substituted cycloalkyleneimino group which optionally contains further heteroatoms and R 1 and R 2 are defined as mentioned in claim 1:
  • oxidizing agents such as potassium permanganate, potassium chromate, potassium dichromate, chromium (VI) oxide, mercury (II) chloride, selenium (IV) oxide, Lead (IV) oxide, lead (II, IV) oxide, potassium peroxomonosulfate, hydrogen peroxide, sodium hypochlorite, optionally in the presence of a suitable catalyst such as nickel (II) chloride, cobalt (II) chloride, ruthenium (III) chloride, osmium (VIII) oxide , Vanadium (IV) oxide and / or in the presence of a crown ether such as 18-crown-6, in a solvent or
  • oxidizing agents such as potassium permanganate, potassium chromate, potassium dichromate, chromium (VI) oxide, mercury (II) chloride, selenium (IV) oxide, Lead (IV) oxide, lead (II, IV) oxide, potassium peroxomonosulfate, hydrogen peroxide, sodium hypoch
  • Solvent mixture such as water, formic acid, acetic acid, ethyl acetate, benzene, pyridine, dichloromethane, chloroform, carbon tetrachloride, optionally under 2-phase conditions in the presence of a suitable phase transfer catalyst such as, for example, tetrabutylammonium chloride, tetrabutylammonium bromide, benzyltriethyltrammoniumchloride or methyl ammonium chloride, optionally in the presence of an acid such as acetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, sodium hydrogen sulfate, sodium dihydrogen phosphate and / or a base such as sodium hydroxide, potassium hydroxide, ammonia, pyridine, potassium phosphate, dipotassium hydrogen phosphate or sodium acetate at temperatures between -30 and 250 ° C., but preferably carried out between 0 and 150 ° C.
  • this reaction can be
  • R 1 and R 2 are defined as mentioned in claim 1.
  • the nucleophilic substitution is advantageously carried out in a solvent or solvent mixture such as ethanol, isopropanol, benzene, chlorobenzene, toluene, xylene, glycol, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, ⁇ / methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, tetrachloromethylene chloride, chloroform / -Ethyl- diisopropylamine, ⁇ / -C ⁇ - 5 alkylmorpholine, ⁇ / -d -5 -alkylpiperidine, ⁇ / -C ⁇ -5 -alkylpyrrolidine, triethylamine, pyridine, for example at temperatures between -30 and 250 ° C, but preferably between 0 and 150 ° C, if appropriate expediently carried out in the presence of bases such as potassium carbonate, sodium carbonate,
  • R 1 and R 2 are defined as mentioned in claim 1 and Z 1 represents a chlorine, bromine or iodine atom or a triflate group.
  • the reaction is advantageously carried out in a solvent or medium mixture such as benzene, toluene, xylene, tetrahydrofuran, dioxane, diethyl ether, tert-butyl methyl ether, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, sulfolane, dimethylformamide, N-methylpyrroiidinone, tetralin, dimethyl sulfoxide, methylene chloride, between chloroform or tetrachl, for example tetrachl 30 and 250 ° C, but preferably between 0 and 150 ° C, expediently in the presence of transition metal catalysts such as nickel on activated carbon, palladium carbon, tetrakis (triphenylphosphine) palladium (0), tris (dibenzylidene acetone) - dipalladium (O) , Palladium (II) acetate, palladium (II
  • R 1 and R 2 are defined as mentioned in claim 1, with a compound of the general formula in which E is a carbonyl, oxycarbonyl, sulfonyl or an optionally substituted on the nitrogen atom of a substituted sulfamoyl group as mentioned in claim 1, G is a chlorine, bromine or iodine atom or an anhydride, ds-alkoxy or benzotriazoloxy group or E and G.
  • Z 4 represents a nucleofugic leaving group, for example a chlorine, bromine or iodine atom, a tosylate, triflate or mesylate group, and n is a number between 2 and 5, individual methylene groups according to the claim 1 mentioned description may additionally be substituted or replaced by heteroatoms, and subsequent intramolecular cyclization by alkylation of the anilidic nitrogen with elimination of the nucleofugic leaving group Z 4 .
  • a nucleofugic leaving group for example a chlorine, bromine or iodine atom, a tosylate, triflate or mesylate group
  • n is a number between 2 and 5
  • individual methylene groups according to the claim 1 mentioned description may additionally be substituted or replaced by heteroatoms, and subsequent intramolecular cyclization by alkylation of the anilidic nitrogen with elimination of the nucleofugic leaving group Z 4 .
  • the acylation / sulfonylation is advantageously carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, N-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride,
  • a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, N-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride,
  • bases such as pyridine, triethylamine, p-dimethylaminopyridine, potassium carbonate, sodium carbonate, potassium ferf-butoxide, sodium methoxide, sodium ethanolate or basic ion
  • the subsequent intramolecular alkylation is expediently carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, dimethyl sulfoxide, sulfolane, methylene chloride, carbon tetrachloride, / V-ethyl-diisopropylamine, ⁇ / -C ⁇ - / V-C ⁇ -5-alkylpiperidine, ⁇ -C ⁇ - 5 alkylpyrrolidine, triethylamine, pyridine, for example at temperatures between -30 and 250 ° C, but preferably between 0 and 150 ° C, advantageously in the presence of bases such as pyridine, triethylamine , Potassium carbonate, sodium carbonate, potassium te / f.-butylate, sodium methanolate, sodium ethanolate, sodium hydride, potassium hex
  • Y 1 represents a hydroxyl, amino or thiol function optionally blocked by a corresponding protective group and n represents a number between 0 and 4, on the aromatic of the general formula
  • Z 2 and Z 3 nucleofugic leaving groups such as chlorine, bromine or iodine atoms or triflate, mesylate or tosylate groups
  • E represents the carbonyl or sulfonyl group and n represents a number between 0 and 4, individual methylene groups as described in claim 1 substituted or replaced by optionally substituted heteroatoms or other groupings.
  • the initial nucleophilic aromatic substitution is carried out, for example, as described under (a) 1) i) a) i). This is optionally followed by the deblocking of the nucleophilic group Y 1 by methods known from the literature or as generally described below.
  • the reaction of the resulting compound with the compound of the general formula (X) is advantageously carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, N-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride, chloroform , Carbon tetrachloride, / V-ethyl-diisopropylamine, ⁇ / -C ⁇ -5 alkylmorpholine, ⁇ / -C ⁇ -5 alkylpiperidine, / V-C ⁇ -5 -alkylpyrrolidine, triethylamine, pyridine, for example at temperatures between -30 and 250 ° C, but preferably between 0 and 150 ° C, expediently carried out in the presence of bases such as pyridine, triethylamine, p
  • E is a carbonyl, oxycarbonyl, sulfonyl or an optionally on the nitrogen atom of a substituted sulfamoyl group as mentioned in claim 1
  • G is a chlorine, bromine or iodine atom or an anhydride, C ⁇ -5 -alkoxy or benzotriazoloxy group or E and G together represents an isocyano group
  • Z 4 represents a nucleofugic leaving group, for example a chlorine, bromine or iodine atom, a tosylate, triflate or mesylate group, and n is a number between 2 and 5, with individual methylene groups according to the one in claim 1 can be additionally substituted or replaced by heteroatoms, and subsequent intramolecular cyclization by alkylation of the anilidic nitrogen with elimination of the nucleofugic leaving group Z 4 .
  • the alkylation is advantageously carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, dimethyl sulfoxide, sulfolane, methylene chloride, carbon tetrachloride, / V-ethyl-diisopropylamine, amin / -C ⁇ -5-alkylmorphine -d -5 -alkylpiperidine, /V-Ci.s- alkylpyrrolidine, triethylamine, pyridine, for example at temperatures between -30 and 250 ° C, but preferably between 0 and 150 ° C, advantageously in the presence of bases such as pyridine, triethylamine, Potassium carbonate, sodium carbonate, potassium tert-butoxide, sodium methoxide, sodium ethanolate, sodium hydride, potassium hexamethyldisil
  • the subsequent intramolecular acylation / sulfonylation is expediently carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, / V-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride, tetrachloromethane, tetrachloromethane, diamine, diamine, tetramine , ⁇ / -C ⁇ -5 alkylmorpholine, / V-C ⁇ - 5 alkylpiperidine, ⁇ / -C ⁇ - 5 alkylpyrrolidine, triethylamine, pyridine, for example at temperatures between -30 and 250 ° C, but preferably between 0 and 150 ° C., expediently carried out in the presence of bases such as pyridine, triethyl
  • a nucleofugic leaving group such as a bromine or chlorine atom or a tosylate, triflate or mesylate group
  • Y 1 is a nucleophilic group such as a hydroxyl or an optionally substituted amino group which is optionally blocked by a suitable protective group
  • m is a number between 2 and 5, wherein individual methylene groups can be additionally substituted or replaced by heteroatoms as described in claim 1, with subsequent acylation / sulfonylation with a compound of the general formula
  • E is a carbonyl, oxycarbonyl, sulfonyl or an optionally on the nitrogen atom of a substituted sulfamoyl group as mentioned in claim 1
  • G is a chlorine, bromine or iodine atom or an anhydride, C ⁇ -5 -alkoxy or benzotriazoloxy group or E and G together represent an isocyanato or cyano group
  • Z 4 represents a nucleofugic group, for example a bromine or chlorine atom or a tosylate, triflate or mesylate group, and n is a number between 2 and 5, with individual methylene groups according to that in claim 1
  • the above-mentioned description can be additionally substituted or replaced by heteroatoms, and subsequent intramolecular cyclization by alkylation of the optionally previously deblocked nucleophilic group Y 1, with the nucleofugic leaving group Z 4 being split off.
  • Both the necessary alkylations and the acylation / sulfonylation can be carried out analogously to the conditions described under (a) 1) i) b) or (a) 1) i) d).
  • R 1 and R 2 are defined as mentioned in claim 1, and which can be obtained by methods known from the literature from compounds of the general formula (VIII), for example by reaction with phosgene in toluene, with a compound of the general formula in which Z 6 represents a nucleofugic leaving group, for example a chlorine, bromine or iodine atom, a tosylate, triflate or mesylate group, and E represents a hydroxyl, amino or C 3 -3 alkylamino function and n is a number between 2 and 4 , where individual methylene groups can additionally be substituted as described in claim 1, and subsequent intramolecular cyclization by alkylation of the anilidic nitrogen with elimination of the nucleofugic leaving group Z 6 .
  • Z 6 represents a nucleofugic leaving group
  • Z 6 represents a nucleofugic leaving group
  • E represents a hydroxyl, amino or C 3 -3 alkylamino function
  • n is a number between 2 and 4
  • the carbamoylation is advantageously carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, N-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride,
  • a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, N-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride,
  • the subsequent intramolecular alkylation is carried out, for example, analogously to that described under (a) 1) i) b).
  • the reaction is expediently carried out in a solvent or solvent mixture such as benzene, toluene, xylene, tetrahydrofuran, dioxane, diethyl ether, tert-butyl methyl ether, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, sulfolane, dimethylformamide, N-methylpyrrolidinone, tetralin, dimethyl sulfoxide, methoxide or carbon tetrachloride, for example at temperatures between -30 and 250 ° C, but preferably between 0 and 200 ° C, advantageously in the presence of transition metal catalysts such as tetrakis (triphenylphosphine) palladium (O), tris (dibenzylidene acetone) dipalladium ( 0), palladium (II) acetate, palladium (II) chloride, bis (triphenylphoshin) palladium (II) chlor
  • tricyclohexylphosphine palladium (II) chloride, bis (triethylphosphine) palladium (II) chloride, bis (tri-o-tolylphosphine) palladium (II) chloride, optionally in the presence of ligands such as triphenylphosphine, tri -o-tolylphosphine, T ⁇ -tert.-butylphosphine, 1, 3-bis (diphenylphosphino) propane, 2,2'-bis (diphenylphosphino) -1, 1 'dinaphthyl, 1, 1'-bis ( diphenylphosphino) ferrocene, xantphos, or for example in the presence of a transition metal catalyst such as copper (l) iodide, copper (l) bromide or copper (l) acetate and advantageously in the presence of a base such as tetramethylguanidine, tetramethylethylene
  • Z 7 represents an optionally substituted amino group or the nitro group
  • E represents an optionally substituted aminocarbonyl, aminosulfonyl group or a carbonyl or sulfonyl group corresponding to the description mentioned in claim 1, where I and o independently of one another represent the same or different numbers between 1 and 3, which by a sequence of alkylation and acylation / sulfonylation / carbamoylation / sulfamoylation with corresponding reagents according to those already described here, for example, under (a) 1) i) c) or other known from the literature Processes can be obtained, optionally followed by reduction, if Z 7 represents a nitro group, after the procedure described under (a) 1) i) and / or hydrogenation of the resulting double bond, analogously to the processes described under (a) 1) i).
  • the ring closure by metathesis reaction is expediently carried out in a solvent or solvent mixture such as benzene, chlorobenzene, toluene, xylene, methanol, ethanol, propanol, diethyl ether, Tetrahydrofuran, dioxane, glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, / V-methylpyrrolidinone, tetralin, dimethyl sulfoxide, sulfolane, methylene chloride, chloroform, carbon tetrachloride, pyridine, in the presence of a catalyst such as benzylidene-bis- (tricyclohexdichlorophosphine (1st generation Grubbs catalyst) or benzylidene [1,3-bis (2,4,6-trimethylphenyl) -2-imidazolidinylidene] dichloro (tricyclohexylphosphine) ruthenium (2nd generation Gr
  • R 3 aldehyde (formaldehyde or paraformaldehyde for R 3 methyl, acetaldehyde or paraldehyde for R 3 ethyl, propionaldehyde for R 3 propyl) is advantageously carried out in a solvent or solvent mixture such as methanol, ethanol, propanol, isopropanol, Butanol, tetrahydrofuran, dioxane, diethyl ether, t-butyl methyl ether, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, sulfolane, dimethylformamide, / V-methylpyrrolidinone, tetralin, dimethyl sulfoxide, methylene chloride, chloroform or tetrachloromethane, for example at temperatures between -30 ° C , but preferably between -10 and 150 ° C, optionally in the presence of a base such as sodium methoxid
  • the thionation is expediently carried out, for example, in a solvent or solvent mixture such as pentane, hexane, cyclohexane, heptane, benzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dioxane, tetrahydrofuran, dichloromethane, chloroform, tetrachloromethane, 1, 2-dichloroethyrolidine / or else / V-ethyl-diisopropylamine, / V-C ⁇ -5- alkylmorpholine, ⁇ / -C ⁇ - 5 -alkylpiperidine, ⁇ / -C ⁇ -5 -alkylpyrrolidine, triethylamine, pyridine, with reagents such as phosphorus pentasulfide, 2,2- Bis- (4-methoxyphenyl) -1, 3,2,4-di
  • any subsequent alkylation of the corresponding thiocarbonyl compounds is expediently carried out, for example, in a solvent or solvent mixture such as pentane, hexane, cyclohexane, heptane, benzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dioxane, tetrahydrofuran, dichloromethane, chloroform, 1-tetrachloromethane , Chlorobenzene, pyridine, water, methanol, ethanol, n-propanol, iso-propanol, n-butanol, acetone, butanone, acetonitrile or nitromethane, optionally under 2-phase conditions with the addition of a phase transfer catalyst such as tetrabutylammonium chloride, tetrabutyl -ammonium bromide, methyl-trioctyl-ammonium chloride
  • reaction following an alkylation with an amino compound to produce the corresponding imine is expediently carried out, for example, in a solvent or solvent mixture such as pentane, hexane, cyclohexane, heptane, benzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dioxane, tetrahydrofuran, dichloromethane,
  • a solvent or solvent mixture such as pentane, hexane, cyclohexane, heptane, benzene, toluene, xylene, glycol dimethyl ether, diethylene glycol dimethyl ether, dioxane, tetrahydrofuran, dichloromethane,
  • a base such as sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, pyridine, tri
  • iii thionylation of the corresponding carbonyl-analogue compound of the general formula (II), which can be obtained by the processes described under (a) 1) i), ii), iii) and (a) 2), optionally with subsequent alkylation of the Sulfur and reaction with a correspondingly substituted amine (for example methylamine, hydroxylamine, acetoxyamine, methoxyamine, cyanamide or corresponding analogous compounds), the aniline amino group present being expediently blocked in a possible subsequent alkylation by suitable protective groups which are split off after conversion to the imine ,
  • a correspondingly substituted amine for example methylamine, hydroxylamine, acetoxyamine, methoxyamine, cyanamide or corresponding analogous compounds
  • R 6 is defined as mentioned in claim 1 and Q represents a hydroxy or -CC 4 alkoxy group, a halogen atom or an acyloxy group.
  • the acylation is advantageously carried out using an appropriate halide or anhydride in a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile, dimethylformamide, sodium hydroxide solution or sulfolane optionally in the presence of an inorganic or organic base at temperatures between -20 and 200 ° C, but preferably at Temperatures between -10 and 160 ° C, carried out.
  • a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile, dimethylformamide, sodium hydroxide solution or sulfolane optionally in the presence of an inorganic or organic base at temperatures between -20 and 200 ° C, but preferably at Temperatures between -10 and
  • the acylation can also be carried out with the free acid, if appropriate in the presence of an acid-activating agent or a dehydrating agent, for example in the presence of
  • the protective group Z 9 can subsequently be split off by processes known from the literature for the following reactions.
  • the acylation can be carried out analogously to that described under (b) 1).
  • the acylation can also be conveniently carried out in a solvent or solvent mixture such as dichloromethane, trichloromethane, benzene, chlorobenzene, toluene, xylene, hexamethyldisiloxane, acetonitrile, / V-ethyl-diisopropylamine, ⁇ / -C ⁇ -5- alkylmorpholine, / V-C ⁇ -5 -Alkylpiperidin, ⁇ / -C 1 -5- alkylpyrrolidine, triethylamine, pyridine, in the presence of 4-trifluoromethylbenzoic anhydride, silver triflate and titanium (IV) chloride, advantageously in In the presence of a dehydrating agent such as molecular sieve, sodium sulfate, magnesium sulfate, or in the presence of 4-trifluoromethyl-benzoic anhydride and ytterbium (III) triflate,
  • Compounds of the general formula (XXI) can be obtained by processes known from the literature, and in the case of R 4 and R 5 not equal to hydrogen, for example according to those described in C. Cativiela, MD Diaz-de-Villegas, Tetrahedron Asymm., 1998, 9, 3517-3599 or C. Cativiela, MD Diaz-de-Villegas, Tetrahedron Asymm., 2000, 11, 645-732.
  • R 4 to R 6 are defined as mentioned in claim 1.
  • acylation is expediently carried out in a solvent or solvent mixture such as dichloromethane, trichloromethane,
  • a Lewis acid such as aluminum chloride, zinc iodide, zinc chlor
  • Compounds of the general formula (XXIII) can advantageously be obtained from compounds of the general formula (XXII) in a solvent or solvent mixture, such as dichloromethane, trichloromethane, carbon tetrachloride, benzene, chlorobenzene, toluene, xylene, hexamethyldisiloxane, ether, tetrahydrofuran, dioxane, acetonitrile, pyridine, if appropriate in the presence of ⁇ /, / V-dicyclohexylcarbodiimide, ⁇ /./ V-dicyclohexylcarbodiimide // V-hydroxysuccinimide or 1-hydroxy-benzotriazole, ⁇ /./ V-carbonyldiimidazole, 0- (benzotriazol-1-yl) - / V, / V, / V, / V-tetramethyl uroniumtetraflu
  • any reactive groups present such as hydroxyl, carboxy, amino, alkylamino or imino groups
  • the protective radical for a hydroxyl group is the methoxy, benzyloxy, trimethylsilyl, acetyl, benzoyl, fe / t-butyl, trityl, benzyl or tetrahydropyranyl group, as protective residues for a carboxyl group, the trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl group and
  • the subsequent subsequent splitting off of a protective residue used takes place, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by means of ether cleavage, e.g. B. in the presence of iodotrimethylsilane, at temperatures between 0 and 100 ° C, preferably at temperatures between 10 and 50 ° C.
  • an aqueous solvent e.g. in water, isopropanol / water, tetrahydrofuran / water or dioxane / water
  • an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid
  • an alkali base such as lithium hydro
  • a benzyl, methoxybenzyl or benzyloxycarbonyl residue is split off, for example by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide,
  • Dimethylformamide / acetone or glacial acetic acid optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 50 ° C., but preferably at room temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably from 1 to 5 bar.
  • an acid such as hydrochloric acid at temperatures between 0 and 50 ° C., but preferably at room temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably from 1 to 5 bar.
  • a methoxybenzyl group can also be split off in the presence of an oxidizing agent such as cerium (IV) ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile / water at temperatures between 0 and 50 ° C, but preferably at room temperature.
  • an oxidizing agent such as cerium (IV) ammonium nitrate
  • a solvent such as methylene chloride, acetonitrile or acetonitrile / water at temperatures between 0 and 50 ° C, but preferably at room temperature.
  • a methoxy group is advantageously eliminated in the presence of boron tribromide in a solvent such as methylene chloride at temperatures between -35 and -25 ° C.
  • a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.
  • a te / i-butyl or fe / t-butoxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxane or ether.
  • a phthalyl radical is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at temperatures between 20 and 50 ° C.
  • An allyloxycarbonyl radical is split off by treatment with a catalytic amount of tetrakis (triphenylphosphine) palladium (0), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of a base such as morpholine or 1,3-dimedone at temperatures between 0 and 100 ° C, preferably at room temperature and under inert gas, or by treatment with a catalytic amount of tris (triphenylphosphine) rhodium (l) chloride in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4-diazabicyclo [2.2. 2] octane at temperatures between 20 and 70 ° C.
  • a catalytic amount of tetrakis (triphenylphosphine) palladium (0) preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of
  • the compounds of general Formula I which occur in racemates, according to methods known per se (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) in their optical antipodes and compounds of the general formula I with at least two asymmetrical ones Due to their physicochemical differences, carbon atoms can be separated into their diastereomers by methods known per se, for example by chromatography and / or fractional crystallization, which, if they occur in racemic form, can then be separated into the enantiomers as mentioned above.
  • the separation of enantiomers is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols, and separation of the diastereomeric salt mixture or derivative obtained in this way, e.g. due to different solubilities, it being possible for the free antipodes to be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols
  • Suitable optically active alcohols are, for example, (+) - or (-) - menthol, and optically active acyl radicals in amides are, for example, the (+) - or (-) - menthyloxycarbonyl radicals.
  • the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids.
  • suitable acids for this purpose are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • the new compounds of formula I thus obtained if they contain a carboxy group, can then optionally be converted into their salts with inorganic or organic bases, in particular for their pharmaceutical use into their physiologically tolerable salts.
  • Suitable bases here are, for example, sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
  • Formula I and their tautomers, their enantiomers, their diastereomers and their physiologically tolerable salts have valuable pharmacological properties, in particular an antithrombotic activity, which is preferably based on an action which influences thrombin or factor Xa, for example an action which inhibits thrombin or factor Xa an aPTT time prolonging effect and / or an inhibitory effect on related serine proteases such as.
  • B. urokinase, factor VIIa, factor IXa, factor Xal and factor Xlla are valuable pharmacological properties, in particular an antithrombotic activity, which is preferably based on an action which influences thrombin or factor Xa, for example an action which inhibits thrombin or factor Xa an aPTT time prolonging effect and / or an inhibitory effect on related serine proteases such as.
  • Enzyme kinetic measurement with a chromogenic substrate The amount of p-nitroaniline (pNA) released from the colorless chromogenic substrate by human factor Xa is determined photometrically at 405 nm. It is proportional to the activity of the enzyme used. The inhibition of the enzyme activity by the test substance (based on the solvent control) is determined at different test substance concentrations and from this the IC 50 is calculated as the concentration which inhibits the factor Xa used by 50%.
  • pNA p-nitroaniline
  • Substrate S 2765 (Chromogenix), final concentration: 0.3 mM / l (1 KM) per reaction mixture
  • Test substance final concentration 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 ⁇ mol / l
  • the compounds prepared according to the invention are generally well tolerated.
  • the new compounds and their physiologically tolerable salts are suitable for the prevention and treatment of venous and arterial thrombotic diseases, such as, for example, the prevention and treatment of deep vein thrombosis, the prevention of reocclusion after bypass surgery or angioplasty (PT ( C) A), as well as occlusion in peripheral arterial diseases, as well as prevention and treatment of pulmonary embolism, disseminated intravascular coagulation and severe sepsis, prevention and prophylaxis of DVT in patients with exacerbation of COPD, treatment of uicerative colitis, prophylaxis and treatment of coronary thrombosis, prophylaxis of stroke, and prevention of occlusion of shunts.
  • venous and arterial thrombotic diseases such as, for example, the prevention and treatment of deep vein thrombosis, the prevention of reocclusion after bypass surgery or angioplasty (PT ( C) A), as well as occlusion in peripheral arterial diseases, as well as prevention
  • the compounds according to the invention are for antithrombotic support in thrombolytic treatment, such as, for example, with alteplase, reteplase, tenecteplase, staphylokinase or streptokinase, for preventing long-term restenosis after PT (C) A, for the prophylaxis and treatment of ischemic incidents in patients of all forms coronary heart disease, to prevent metastasis and growth of tumors and inflammatory processes, e.g. suitable for the treatment of pulmonary fibrosis, for the prophylaxis and treatment of rheumatoid arthritis, for the prevention or prevention of fibrin-dependent tissue adhesions and / or scar tissue formation and for the promotion of wound healing processes.
  • C PT
  • the new compounds and their physiologically tolerable salts are also suitable for the treatment of Alzheimer's and Parkinson 's diseases.
  • a rational this results, for example, from the following findings, from which it can be concluded that thrombin inhibitors or factor Xa inhibitors, by inhibiting thrombin formation or activity, could represent valuable medicaments in the treatment of Alzheimer's and Parkinson 's disease.
  • Clinical and experimental studies suggest that neurotoxic mechanisms, for example the inflammation associated with the activation of proteases in the coagulation cascade, are involved in the death of neurons as a result of brain trauma.
  • thrombin is involved in neurodegenerative processes, for example as a result of a stroke, repeated bypass surgery or traumatic brain injuries.
  • thrombin causes neurite retraction, as well as glia proliferation and apoptosis in primary cultures of neurons and neuroblastoma cells (for an overview, see: Neurobiol. Aging 2004, 25 (6), 783-793).
  • various in vitro studies on the brains of patients with Alzheimer's disease indicate that thrombin plays a role in the pathogenesis of this disease (Neurosci. Lett. 1992, 146, 152-54). Enrichment of immunoreactive thrombins has been demonstrated in neurite plaques in the brains of Alzheimer's patients.
  • thrombin also plays a role in the regulation and stimulation of the production of the "amyloid precursor protein” (APP) and in the cleavage of the APP into fragments which are detected in the amyloid plaques in the brain of Alzheimer's patients can. Furthermore it could be shown that thrombin-induced microglial activation leads to degeneration of nigral dopaminergic neurons in vivo. These findings lead to the conclusion that microglial activation - triggered by endogenous substance (s) such as thrombin - is involved in the neuropathological process of cell death of dopaminergic neurons, as occurs in patients with Parkinson 's disease (J. Neurosci. 2003, 23 , 5877-86).
  • endogenous substance s
  • the dosage required to achieve an appropriate effect is expediently in the case of intravenous administration 0.01 to 3 mg / kg, preferably 0.03 to 1.0 mg / kg, and in the case of oral administration 0.03 to 30 mg / kg, preferably 0.1 to 10 mg / kg, in each case 1 to 4 times a day.
  • the compounds of formula I prepared according to the invention optionally in combination with other active substances, together with one or more inert customary carriers and / or diluents, e.g. with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin,
  • inert customary carriers and / or diluents e.g. with corn starch, milk sugar, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin,
  • the new compounds and their physiologically tolerable salts can be used therapeutically in combination with acetylsalicylic acid, with platelet aggregation inhibitors such as fibrinogen receptor antagonists (for example abciximab, eptifibatide, tirofiban, roxifiban), with physiological activators and inhibitors of the coagulation system and their recombinant analogs, for example C, TFPI, antithrombin), with inhibitors of ADP-induced aggregation (e.g. clopidogrel, ticlopidine), with P 2 T receptor antagonists (e.g. Cangrelor) or with combined thromboxane receptor antagonists / synthetase inhibitors (e.g. Terbogrel).
  • fibrinogen receptor antagonists for example abciximab, eptifibatide, tirofiban, roxifiban
  • physiological activators and inhibitors of the coagulation system and their recombinant analogs for example C, TFPI,
  • the ratios given for the flow agents relate to volume units of the respective solvents.
  • Silica gel from Millipore MATREX TM, 35-70 ⁇ m was used for chromatographic purifications. If further details on the configuration are missing, it remains open whether it is pure stereoisomers or enantiomer / diastereomer mixtures.
  • HATU 0 (7-azabenzotriazol-1-yl) - / V, / V, / V ', / V'-tetramethyluronium hexafluorophosphate i. Vak. in a vacuum conc. Concentrated min minute (s)
  • HPLC / MS data were, as far as stated, generated under the following conditions: HP 1100 with quaternary pump, Gilson G215 autosampler, HP diode array detector.
  • the mobile phase used was: A: water with 0.1% TFA B: acetonitrile with 0.08% TFA
  • the diode array detection was carried out in the wavelength range 210-550 nm range of the mass spectrometric detection: mz 120 to m / z 1000.
  • example 1
  • the remaining half of the sodium methoxide solution is then added, the mixture is stirred for another hour at room temperature, and then 20 ml (45.60 g, 0.32 mol) of iodomethane are added. The mixture is then stirred for 18 hours at room temperature under a nitrogen atmosphere. The reaction mixture is i. Vak. restricted, the
  • the residue is dissolved in water and extracted with diethyl ether.
  • the aqueous phase is brought to pH 4 with citric acid solution and extracted with ethyl acetate.
  • the combined organic phases are saturated with sat. Washed sodium chloride solution, dried over sodium sulfate and i. Vak. concentrated.
  • the residue is taken up in dichloromethane and water, with

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nouveaux thiophène-2-carboxamides substitués, de formule générale (I) dans laquelle A et R<1> à R<8c> sont tels que définis dans la revendication 1, leurs tautomères, leurs énantiomères, leurs diastéréomères, leurs mélanges et leurs sels, en particulier leurs sels physiologiquement compatibles contenant des acides ou bases inorganiques ou organiques, qui possèdent des propriétés précieuses.
EP05747401A 2004-05-13 2005-05-07 Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments Withdrawn EP1747217A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05747401A EP1747217A1 (fr) 2004-05-13 2005-05-07 Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04011384 2004-05-13
EP04018807 2004-08-07
PCT/EP2005/004975 WO2005111029A1 (fr) 2004-05-13 2005-05-07 Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments
EP05747401A EP1747217A1 (fr) 2004-05-13 2005-05-07 Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments

Publications (1)

Publication Number Publication Date
EP1747217A1 true EP1747217A1 (fr) 2007-01-31

Family

ID=34969085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05747401A Withdrawn EP1747217A1 (fr) 2004-05-13 2005-05-07 Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments

Country Status (13)

Country Link
US (1) US7476663B2 (fr)
EP (1) EP1747217A1 (fr)
JP (1) JP2007537180A (fr)
KR (1) KR20070012552A (fr)
AR (1) AR048959A1 (fr)
AU (1) AU2005243535A1 (fr)
BR (1) BRPI0510019A (fr)
CA (1) CA2564207A1 (fr)
IL (1) IL179170A0 (fr)
MX (1) MXPA06013213A (fr)
RU (1) RU2006143842A (fr)
TW (1) TW200604178A (fr)
WO (1) WO2005111029A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1748996A1 (fr) * 2004-05-13 2007-02-07 Boehringer Ingelheim International GmbH Amides substitues de l'acide thiophene-carboxylique, leur production et leur utilisation comme medicament
WO2005111013A1 (fr) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Amides d'acide thiophene-2-carboxylique substitues, leur production et leur utilisation comme medicament
DE102004062544A1 (de) * 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP2220079A2 (fr) 2007-11-15 2010-08-25 Boehringer Ingelheim International GmbH Amides substitués, leur fabrication et utilisation sous forme de médicaments
WO2009119528A1 (fr) * 2008-03-24 2009-10-01 武田薬品工業株式会社 Composé hétérocyclique
US20100168377A1 (en) * 2008-12-29 2010-07-01 Carter Technologies Catalytic conversion of amide compounds to methyl ether polymers and methyl ether ladder polymers
ITBO20090078A1 (it) 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010123792A1 (fr) * 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Préparation de c-pyrazine-méthylamines
EP2630143B1 (fr) * 2010-10-18 2017-11-29 Apotex Pharmachem Inc. Procédés de préparation de rivaroxaban et ses intermédiaires
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
WO2012149102A1 (fr) * 2011-04-29 2012-11-01 Glaxosmithkline Llc Nouveaux composés en tant qu'inhibiteurs de wip1
GB201820166D0 (en) * 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
US11795147B2 (en) 2019-08-26 2023-10-24 Boehringer Ingelheim International Gmbh Modulators of complex I
JP7502564B2 (ja) * 2020-11-06 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２－［（チオフェン－２－イル）ホルムアミド］－ｎ－（フェニル）－２－メチルプロパンアミド誘導体及びその医薬としての使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
MY130373A (en) * 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
WO2004031145A2 (fr) 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Diaminoalkyle contenant du lactame, acides amines beta, acides amines alpha et leurs derives utilises en tant qu'inhibiteurs du facteur xa
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
DE10301419A1 (de) * 2003-01-16 2004-07-29 Bayer Cropscience Ag Spiroverbindungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005111029A1 *

Also Published As

Publication number Publication date
KR20070012552A (ko) 2007-01-25
IL179170A0 (en) 2007-03-08
CA2564207A1 (fr) 2005-11-24
BRPI0510019A (pt) 2007-09-25
TW200604178A (en) 2006-02-01
MXPA06013213A (es) 2007-02-08
AU2005243535A1 (en) 2005-11-24
US20050277628A1 (en) 2005-12-15
WO2005111029A1 (fr) 2005-11-24
US7476663B2 (en) 2009-01-13
JP2007537180A (ja) 2007-12-20
AR048959A1 (es) 2006-06-14
RU2006143842A (ru) 2008-08-20

Similar Documents

Publication Publication Date Title
EP2132193B1 (fr) Pyrrolidinamides substitués, leur fabrication et leur utilisation en tant que médicament
EP2051975B1 (fr) Prolinamides substitués, procédé de production et utilisation de ceux-ci comme médicaments
EP1771441B8 (fr) Nouveaux carboxamides comme inhibiteurs du facteur xa
EP1747217A1 (fr) Nouveaux thiophene-carboxamides substitues, leur production et leur utilisation en tant que medicaments
EP1899330B9 (fr) Glycinamides substitues a effet antithrombotique et inhibant le facteur xa
EP1987021B1 (fr) Proline-amides substituées, leur préparation et leur utilisation comme médicaments
WO2007025940A1 (fr) Biaryles substitues et leur utilisation comme inhibiteurs du facteur xa
DE102004047840A1 (de) Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE102004062544A1 (de) Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
WO2005111013A1 (fr) Amides d&#39;acide thiophene-2-carboxylique substitues, leur production et leur utilisation comme medicament
WO2007009963A1 (fr) Amides substitues, leur preparation et leur utilisation en tant que medicament
US7732466B2 (en) Substituted thiophene carboxamides, process for their preparation and their use as medicaments
DE102004009835A1 (de) Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE102004060984A1 (de) Neue Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE19751939A1 (de) Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: BA HR YU

RAX Requested extension states of the european patent have changed

Extension state: YU

Payment date: 20061213

Extension state: HR

Payment date: 20061213

Extension state: BA

Payment date: 20061213

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

17Q First examination report despatched

Effective date: 20090506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110514